

Universidad Peruana Cayetano Heredia

Research projects funded by United States federal funds, through contracts and subcontracts entered into between Universidad Peruana Cayetano Heredia and the National Institutes of Health (NIH) and universities of the United States of America.

Audit report on the Statements of Expenditures for the period from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

Research projects funded by United States federal funds, through contracts and subcontracts entered into between Universidad Peruana Cayetano Heredia and the National Institutes of Health (NIH) and universities of the United States of America.

Audit report on the Statements of Expenditures for the period from January 1, 2025 to December 31, 2025.

Contents

- I. Independent Auditors' Report**
- II. Introduction**
- III. General information on the Research Projects**
 - 3.1. Legal incorporation of Universidad Peruana Cayetano Heredia.
 - 3.2. Funding of the Research Projects.
 - 3.3. Consolidated Statement of Expenditures of the Research Projects.
 - 3.4. Individual Statements of Expenditures of the Research Projects.
- IV. Background and scope of work**
- V. Financial, accounting and administrative verification**
 - 5.1. Main accounting policies.
 - 5.2. Audit procedures for expenditures of the Research Projects.
- VI. Internal Control**
- VII. Compliance with the terms of the contracts, subcontracts, laws and applicable regulations**
- VIII. Opportunities for improvement and recommendations**
- IX. Follow-up on recommendations from prior periods**

US\$ = US Dollar

I. INDEPENDENT AUDITORS' REPORT

To the members of the University Council of Universidad Peruana Cayetano Heredia

Opinion

We have audited the Consolidated Statements of Expenditures of seventy-three Research Projects (hereinafter, the Projects) of **Universidad Peruana Cayetano Heredia** (a non-profit educational entity), which are funded by United States federal funds, through contracts and subcontracts between Universidad Peruana Cayetano Heredia and the National Institutes of Health (hereinafter NIH) and various entities of the United States of America, respectively, for the period from January 1, 2025 to December 31, 2025.

In our opinion, the Consolidated Statements of Expenditures present fairly, in all material respects, the expenditures incurred by the research projects, executed by Universidad Peruana Cayetano Heredia and funded directly by the National Institutes of Health (NIH) and indirectly by NIH through universities of the United States of America, as required by the United States federal entity - National Institutes of Health (NIH) based on 2 CFR Part 200, for the period from January 1, 2025 to December 31, 2025.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISA). Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Statement of Expenditures" section of our report.

We are independent of **Universidad Peruana Cayetano Heredia**, in accordance with the International Code of Ethics for Professional Accountants issued by the International Ethics Standards Board for Accountants (IESBA Code), together with the ethical requirements relevant to our audit of the financial statements in Perú, and we have fulfilled our other ethical responsibilities in accordance with those requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Independent auditors' report (continued)

Special purpose accounting basis

Without qualifying our opinion, we draw attention to Note 5.1 to the Consolidated Statement of Expenditures, which describes the accounting basis used in the preparation of the Consolidated Statement of Expenditures of Federal Funds.

The Consolidated Statement of Expenditures has been prepared to present the expenditures related exclusively to the resources received and used in the execution of the Project, funded with resources from the National Institutes of Health (NIH) and indirectly by NIH through universities of the United States of America in accordance with the terms and conditions established in the respective funding agreement.

Therefore, the financial statements may not be suitable for other purposes.

Responsibilities of the General Administration Office for the Consolidated Statements of Expenditures

The General Administration Office of **Universidad Peruana Cayetano Heredia** is responsible for the preparation and fair presentation of these Statements of Expenditures in accordance with the execution/expenditure basis. This responsibility includes: designing, implementing and maintaining internal control relevant to the preparation and fair presentation of the Consolidated Statements of Expenditures so that they are free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities for the Audit of the Consolidated Statements of Expenditures

Our responsibility is to express an opinion on the Statements of Expenditures of each Research Project based on our audit. Our audit was conducted in accordance with Generally Accepted Government Auditing Standards of the United States of America (GAGAS), the Compliance Supplement of the United States Office of Management and Budget (OMB) - 2 CFR Part 200, and International Standards on Auditing (ISA). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statements of Expenditures are free from material misstatement.

Report on Compliance with Internal Control

The General Administration Office of **Universidad Peruana Cayetano Heredia** is responsible for establishing and maintaining effective internal control. In planning and performing our audit, we considered the internal controls that could have a direct and material effect on expenditures, in order to determine appropriate audit procedures for the purpose of expressing an opinion on the reasonableness of internal control in accordance with 2 CFR Part 200.

Independent auditors' report (continued)

In planning and performing our audit, we considered the internal control that the University has over the financial reporting for management of the projects (internal control) as a basis for designing our audit procedures for the purpose of expressing an opinion on the consolidated statement of expenditures comprising seventy-three (73) research projects, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the entity's internal control.

Countersigned by:

Panez, Chacaliza y Asociados Sociedad Civil de R.L.**Marvin Rodriguez (Partner)**

Certified Public Accountant

License No. 43761

August 10, 2026

Lima, Perú

**Notes to the Statements of Expenditures of the Research Projects funded by United States federal funds, through direct contracts with the National Institutes of Health (NIH) and indirectly with NIH through universities of the United States of America.
For the period from January 1, 2025 to December 31, 2025**

II. INTRODUCTION

This report presents the results of the audit of the following Research Projects, for the period from January 1, 2025 to December 31, 2025:

- P10007 - 1/2 - Regional Geohealth Hub Centered in Perú
- P10012 - Knowledge, attitudes, and exposure to Hepatitis A Virus among medical students at a private university in Lima, Perú
- P10025 - A mobile phone short message service intervention to increase retention in HIV (Weltel Perú)
- P10028 - One-health approach to study Human Fasciola Hepatica transmission and inform strategic control
- P10031 - Markers of triclabendazole resistant fasciolosis the highlands of Perú
- P10036 - D43 Chronic non-communicable CVDC and comorbidities in Perú
- P10038 - Project of febrile illness surveillance in the andean and Amazon Countries (PISAAC)
- P10039 - Statistical methods for correlated outcome and covariate errors in studies of HIV/AIDS
- P10040- Focal mass drug administration (FMDA) to reduce plasmodium vivax transmission, a pragmatic cluster randomized controlled trial in Perú
- P10044 - Training - 2/2 regional Geohealth Hub Centered in Perú-US
- P10055 - How land use change transforms the landscape of vector-Borne Disease
- P10056 - Improving response to Malaria outbreaks in Amazon-basin Countries
- P10060 - University of California Global Health Institute program for fellows and scholars
- P10061 - Genomic Epidemiology of campylobacter to improve disease control in low and middle income Countries
- P10065 - Using burden of treatment as a clinical indicator of barriers to multimorbidity management in Perú: a mixed methods approach
- P10066 - Perú infectious diseases epidemiology research training consortium
- P10068 - Genomic epidemiology of campylobacter in poultry to enable the effective control of human Campylobacteriosis in a middle income Country
- P10071 - Using the mycobacterium Tuberculosis Genome to predict Tuberculosis pathology, drug resistance acquisition and identify community transmission sites
- P10077 - Infectious diseases training program in Bolivia: South - south training with Perú
- P10079 - Understanding immune modulation in Taenia Solium neurocysticercosis by using a novel postoncosphere in vitro model
- P10084 - Alternative therapeutic approaches for the control of brain inflammation secondary to antihelminthic therapy in neurocysticercosis using a novel experimental pig model
- P10089 - Training in infectious diseases in Perú - time for implementation research
- P10108 - ictus: interdisciplinary cerebrovascular diseases training program in South America
- P10113 - Controlled, randomized, multicenter clinical trial of single- and multiple-dose regimens of oxfendazole
- P10119 - Acceptability, feasibility, and preliminary impact of a web-based, hiv prevention toolkit with cisgender male couples in Lima, Perú
- P10121 - Clinical trial comparing the effectiveness of cefixime versus penicillin g for treatment of early sy

P10123 - Fend for TB

P10128 - A non-inferiority randomized single blind controlled trial comparing one and two dose regimes of oxfendazole

P10133 - Longitudinal analysis of immune signatures (IMS) of M. Tuberculosis-specific T cells

P10171 - An immune system for the City: a new paradigm for control of urban disease vectors

P10180 - Multidisciplinary training program on neuropsychiatry and behavioral disorders in first nations (NEUFIN)

P10182 - Research training in chronic, non-communicable respiratory diseases in Perú

P10184- Spatially responsive mass vaccination strategies for Urban Rabies

P10194- Improving national knowledge and awareness of fungal infections in Perú

P10196 - Program for advanced research capacities for AIDS in Perú (Paracas) harnessing implementation science

P10212- Ccasanet 2021 - 2026

P10214- Addressing Hypertension and Diabetes through community-engaged systems in Puno, Perú (Andes study)

P10225- Prevention through vaccination training (prevent) program

P10241 - Isolation and identification of cxcr4 and cxcr7 agonists from traditional phytopharmaceuticals as potential novel drugs for mental disorders

P10279 - Application of novel biomarkers to measure health impacts of Anthropogenic change in the Amazon

P10298 - Diagnostic innovations for pediatric Tuberculosis in Bolivia

P10299 - South American program in HIV prevention research (SAPHIR)

P10300 - Integrated next-generation surveillance in global health: translation to action (insight to action)

P10301 - Expanding the toolbox for the prevention of Sarcopenia and Osteoporosis in Peruvians aging with HIV: a validation study

P10305 - Improving the diagnosis of HIV-associated neurocognitive disorder (HAND) in Latin America: a multimodal approach to HAND in Perú

P10316 - Next-generation sequencing diagnostics to identify etiologies of acute undifferentiated fever in the Peruvian Amazon

P10319 - Cooperasalud II: Technical Assistance to strengthen post-pandemic HIV prevention and control capacities in the Peruvian armed forces

P10323 - Rapid point-of-care assay for diagnosis of neurocysticercosis in seizure patients

P10324 - Enabling infectious disease research capacity in the Peruvian Amazon

P10330 - An integrated approach to understand and diagnose congenital Chagas disease

P10333 - Improving HIV and STI prevention and care for Venezuelan sexual and gender minority migrants in Lima, Perú

P10340 - Integration of smartphone photography for trachoma assessment, visual acuity, and mobile autorefractometry to improve community public health monitoring

P10345 - UJMT launch: training the next generation of leaders in Global Health Research

P10358 - Research ethics training in Latin America - Retama

P10362 - Understanding host-pathogen interactions in patients with Syphilis infection

P10368 - Aphasia Rehabilitation in Perú: current clinical care, facilitators and barriers to achieving best clinical practice.

P10393 - UJMT launch: training the next generation of leaders in global health research - UJMT D43 training program Andes trainee

P10394 - Research training in integration of epidemiology and implementation science for neglected zoonotic disease control in Perú

P10411 - UC Davis multidisciplinary Cancer research training program to advance precision Cancer prevention and care in Latin America

P10438 - COPCORD Lima, Perú: revealing the prevalence of musculoskeletal and rheumatic disorders in people living with HIV: a pilot study

P10442- Biological implications of breast Cancer protective variants in Latin American women with high indigenous American ancestry
P10448 - Perceptions of people working along the device development pipeline
P10451- Evaluation of autoantibodies and atypical B cells as markers of asymptomatic *P. vivax* infections in the Amazon
P10453- Exploring intersectional stigma and health outcomes in older people with HIV (opwh)
P10454- The indigenous peoples' observatory network (IPON): the climate-food-health nexus
P10468 - Metagenomic characterization of pathogens and resistance genes in wastewater in Perú
P10495 - Effectively linking molecular informatics and network analytics to reduce malaria
P10497- A global epidemiology of cognitive impairment and dementia due to Alzheimer's disease and related disorders: the cosmic collaboration
P10503 - Long-term effects of a household air pollution intervention: follow-up of a randomized controlled trial
P10506- Lung ultrasound and artificial intelligence technology for the diagnosis of tuberculosis in low- and middle-income countries
P10519 - D43 research training grant: chronic non-communicable cvds and co-morbidities in Perú
P10548 - Effectively linking molecular informatics and network analytics to reduce Malaria - suny
P10557- Accuracy of novel diagnostic tests for detection of Tuberculosis in adults: fend for TB

III. GENERAL INFORMATION ON THE RESEARCH PROJECTS

3.1 Legal incorporation of Universidad Peruana Cayetano Heredia

Universidad Peruana Cayetano Heredia was created by Supreme Decree No. 018 dated September 22, 1961. It is a non-state, private, non-profit university. Its purpose is to provide higher education, promote and disseminate scientific research in all fields, and professionally prepare its students, as well as promote university outreach activities. It is governed by University Law 30220 and its supplementary regulations, its bylaws, regulations, and directives.

3.2 Funding of the Research Projects

The funding for these Research Projects comes from United States federal funds, specifically from the National Institutes of Health (NIH), through contracts and subcontracts with Universidad Peruana Cayetano Heredia. This funding is provided in two ways: directly between UPCH and NIH; and indirectly, through a subcontract whereby NIH funds a university in the United States of America, which in turn subcontracts research services to UPCH. The period covered by our audit procedures is from January 1, 2025 to December 31, 2025.

3.3 Consolidated Statement of Expenditures of the Research Projects

Below, we present the Consolidated Statement of Expenditures of the Research Projects (*).

(*) As detailed in the Research Projects, these have different annual budget periods, therefore, it is not possible to make a budget versus execution comparison. Accordingly, we present the expenditures executed as indicated in the Terms of Reference for the period from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

CONSOLIDATED STATEMENT OF EXPENDITURES

Of the Research Projects funded by United States federal funds, under contracts and subcontracts entered into between Universidad Peruana Cayetano Heredia and the funding entities.

For the period from January 1, 2025 to December 31, 2025.

Project number	Compensation	Capital assets	Minor assets	Materials and Supplies	Third-party services	Other management expenses	Tax expenses	Administrative expenses (OVERHEAD)	Grand Total
	US\$	US\$	US\$	US\$	US\$	US\$	US\$	US\$	US\$
P10007	194,716	-	230	3,949	41,806	192,757	1,831	16,398	451,687
P10012	-	-	-	-	423	-	-	-	423
P10025	73,857	-	-	-	70	-	-	39,312	113,239
P10028	144,713	-	-	15,999	13,879	705	-	23,140	198,436
P10031	3,529	-	-	373	1,215	-	-	5,296	10,413
P10036	113,369	-	976	203	21,436	38,491	-	18,043	192,518
P10038	341,692	23,103	226	260,028	183,847	122,740	2,243	-	933,879
P10039	6,648	-	-	-	10,090	-	-	1,174	17,912
P10040	303,331	13,570	6,866	54,138	406,475	370	7,041	57,379	849,170
P10044	24,596	1,393	-	314	46,639	68,950	-	9,281	151,173
P10055	8,691	-	-	247	4,672	-	(518)	1,258	14,350
P10056	44,904	-	490	4,078	40,170	-	-	8,066	97,708
P10060	(70)	-	-	-	30	4,500	-	106	4,566
P10061	27,666	-	-	-	480	-	-	2,001	30,147
P10065	9,953	-	-	-	35	-	-	3,934	13,922
P10066	91,654	-	-	3,016	22,772	16,628	-	-	134,070
P10068	207,558	448	398	23,559	8,949	1,408	-	18,240	260,560
P10071	218	-	-	578	39	-	(514)	7,945	8,266
P10077	361	-	-	-	66	-	-	2,816	3,243
P10079	32,760	-	-	11,650	12,401	-	-	10,504	67,315

UNIVERSIDAD PERUANA CAYETANO HEREDIA

CONSOLIDATED STATEMENT OF EXPENDITURES

Of the Research Projects funded by United States federal funds, under contracts and subcontracts entered into between Universidad Peruana Cayetano Heredia and the funding entities.

For the period from January 1, 2025 to December 31, 2025.

Project number	Compensation	Capital assets	Minor assets	Materials and Supplies	Third-party services	Other management expenses	Tax expenses	Administrative expenses (OVERHEAD)	Grand Total
	US\$	US\$	US\$	US\$	US\$	US\$	US\$	US\$	US\$
P10084	68	-	-	-	-	-	-	4,596	4,664
P10089	99,605	2,330	620	15,982	74,725	184,359	1	18,372	395,994
P10108	37,249	2,350		52	26,500	16,267	-	8,515	90,933
P10113	118,001	2,012	2,735	2,922	19,091	-	133	9,839	154,733
P10119	18,961	-	-	-	1,211	-	-	4,064	24,236
P10121	4,078	-	-	-	7,784	-	-	2,296	14,158
P10123	48,719	-	-	2,213	8,095	-	376	7,196	66,599
P10128	82,202	19,492	1,572	73	19,988	57,318	-	13,564	194,209
P10133	16,053	-	84	1,718	4,191	540	-	4,566	27,152
P10171	15,534	-	-	45	3,627	-	-	11,071	30,277
P10180	27,795			915	20,675	64,359	-	-	113,744
P10182	(209)	3,150	822	2,427	6,671	75,604	-	4,698	93,163
P10184	159,032			328	20,932	-	-	13,327	193,619
P10194	106,590	1,500	900	29,433	95,689	3,653	-	32,945	270,710
P10196	21,458				43,730	103,894	-	-	169,082
P10212	41,546	3,827	53	3,068	34,306	588	359	8,957	92,704
P10214	109,036	2,598	11,003	962	8,494	932,255	1,905	11,179	1,077,432
P10225	29,129			26,087	12,489	21,835	-	1,521	91,061
P10241	26,718	3,714	343	9,687	35,918	707	-	11,949	89,036
P10279	2,702	-	-	-	570	83	-	3,294	6,649

UNIVERSIDAD PERUANA CAYETANO HEREDIA

CONSOLIDATED STATEMENT OF EXPENDITURES

Of the Research Projects funded by United States federal funds, under contracts and subcontracts entered into between Universidad Peruana Cayetano Heredia and the funding entities.

For the period from January 1, 2025 to December 31, 2025.

Project number	Compensation	Capital assets	Minor assets	Materials and Supplies	Third-party services	Other management expenses	Tax expenses	Administrative expenses (OVERHEAD)	Grand Total
	US\$	US\$	US\$	US\$	US\$	US\$	US\$	US\$	US\$
P10298	11,764	-	-	27	7,175	-	-	2,891	21,857
P10299	3,530	-	-	-	7,535	-	-	1,600	12,665
P10300	109,769	-	-	-	90	-	-	28,398	138,257
P10301	6,957	2,050	-	713	43,124	16,734	-	2,902	72,480
P10305	30,354	-	-	5,660	11,031	-	240	10,058	57,343
P10316	9,361	-	242	-	165	-	-	4,556	14,324
P10319	222,675	19,034	8,538	64,007	156,748	2,619	-	56,088	529,709
P10323	43,487	-	-	288	2,407	-	-	3,164	49,346
P10324	15,638	-	-	-	1,421	-	-	86	17,145
P10330	12,636	-	2,153	5,637	5,254	-	350	4,878	30,908
P10333	92,232	11,150	845	6,213	8,649	49,815	-	12,942	181,846
P10340	59,794	-	-	2,739	62,729	-	-	14,406	139,668
P10345	2,894	-	-	136	260	-	-	576	3,866
P10358	107,822	-	-	209	9,769	140,099	-	2,354	260,253
P10362	167,685	10,216	-	70,102	51,649	164	218	13,893	313,927
P10368	88	-	-	-	-	-	-	201	289
P10393	-	-	-	97	239	3,240	-	248	3,824
P10394	38,470	19,903	-	841	23,446	55,868	1,532	9,370	149,430
P10411	6,082	-	-	-	10	-	-	520	6,612
P10438	-	1,720	-	396	29,906	18,096	-	4,616	54,734

UNIVERSIDAD PERUANA CAYETANO HEREDIA

CONSOLIDATED STATEMENT OF EXPENDITURES

Of the Research Projects funded by United States federal funds, under contracts and subcontracts entered into between Universidad Peruana Cayetano Heredia and the funding entities.

For the period from January 1, 2025 to December 31, 2025.

Project number	Compensation	Capital assets	Minor assets	Materials and Supplies	Third-party services	Other management expenses	Tax expenses	Administrative expenses (OVERHEAD)	Grand Total
	US\$	US\$	US\$	US\$	US\$	US\$	US\$	US\$	US\$
P10442	20,334	-	-	-	16,210	-	-	2,854	39,398
P10448	3,645	-	-	-	10	-	-	258	3,913
P10451	19,860	-	-	1,055	37,826	289	405	4,962	64,397
P10453	-	-	-	3,268	30,757	28,139	-	4,892	67,056
P10454	-	-	-	-	6,587	-	-	658	7,245
P10468	435	3,278	-	-	-	-	-	-	3,713
P10495	8,002	-	-	-	1,170	-	-	798	9,970
P10497	29,398	-	144	3,225	297	17,755	-	3,888	54,707
P10503	4,761	1,250	170	38	702	-	-	-	6,921
P10506	66,027	-	-	2,664	13,029	-	-	1,321	83,041
P10519	38,623	746	-	3,687	10,832	30,117	-	2,288	86,293
P10548	1,756	-	-	-	-	-	-	-	1,756
P10557	15,610	-	-	442	3	-	-	-	16,055
Totals	3,744,102	148,834	39,410	645,488	1,799,210	2,270,946	15,602	592,508	9,256,100

3.4 Individual Statements of Expenditures of the Research Projects

The Statements of Expenditures for the period from January 1, 2025 to December 31, 2025 funded directly or indirectly by NIH are as follows:

Project P10007

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES**1/2 - Regional Geohealth Hub Centered in Perú**

Research project funded by United States federal funds, under direct contract with the National Institute of Health - NIH.

For the period from January 1, 2025 to December 31, 2025

Investigator: Hartinger Pena, Stella Maria.

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	194,716
Capital assets	-
Minor assets	230
Materials and supplies	3,949
Third-party services	41,806
Other management expenses	192,757
Tax expenses	1,831
Total Direct Costs	435,289
Total Indirect Costs - Overhead	16,398
Total Costs	451,687

Project execution period: From June 2022 to February 2027.

General Objective of the Project: To develop research capacity on air pollution in Perú and study its association with cardiovascular and respiratory conditions - including COVID-19 - and Alzheimer's Disease (AD), where the association with air pollution is not well established.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

Project P10012

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Knowledge, attitudes, and exposure to Hepatitis A Virus among medical students at a private university in Lima, Perú**Research project funded by United States federal funds, under subcontract with University of Alabama at Birmingham****For the period from January 1, 2025 to December 31, 2025****Investigator: Munoz Cisneros, Helga de los Angeles**

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	-
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	423
Other management expenses	-
Tax expenses	-
Total Direct Costs	423
Total Indirect Costs - Overhead	-
Total Costs	423

Project execution period: From April 2023 to May 2026General Objective of the Project: To determine the level of knowledge about Hepatitis A Virus infection among medical students at a university in Lima, Perú

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

A mobile phone short message service intervention to increase retention in HIV (WELTEL PERÚ)

Research project funded by United States federal funds, under direct contract with the National Institute of Health - NIH.

For the period from January 1, 2025 to December 31, 2025

Investigator: Menacho Alvirio, Luis Alberto.

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	73,857
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	70
Other management expenses	-
Tax expenses	-
Total Direct Costs	73,927
Total Indirect Costs - Overhead	39,312
Total Costs	113,239

Project execution period: From August 2020 to May 2026.

General Objective of the Project: We will determine the efficacy of a text message (SMS) based intervention, delivered through a web-based system, to increase retention in HIV care compared to standard care. To do so, we will conduct a randomized controlled trial. The primary outcome to be evaluated will be retention in HIV care within the first year following enrollment.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

Project P10028

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

One - Health approach to study Human Fasciola Hepatica transmission and inform strategic Control

Research project funded by United States federal funds, under subcontract with Texas Medical Branch University.

For the period from January 1, 2025 to December 31, 2025

Investigator: Montes Delgado, Martin

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	144,713
Capital assets	-
Minor assets	-
Materials and supplies	15,999
Third-party services	13,879
Other management expenses	705
Tax expenses	-
Total Direct Costs	175,296
Total Indirect Costs - Overhead	23,140
Total Costs	198,436

Project execution period: From April 2022 to March 2027.

General Objective of the Project: To determine the critical steps in the transmission of Fasciola hepatica infection to humans by analyzing environmental, temporal-spatial and infection distribution data across the different hosts, using a one-health approach.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Markers of triclabendazole resistant fasciolasis the Highlands of Perú

Research project funded by United States federal funds, under subcontract with Texas Medical Branch University.

For the period from January 1, 2025 to December 31, 2025

Investigator: Gotuzzo Herencia, Jose Eduardo.

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	3,529
Capital assets	-
Minor assets	-
Materials and supplies	373
Third-party services	1,215
Other management expenses	-
Tax expenses	-
Total Direct Costs	5,117
Total Indirect Costs - Overhead	5,296
Total Costs	10,413

Project execution period: From August 2019 to September 2025

General Objective of the Project: The research project has the following general objectives:

- To detect candidate genetic markers associated with Triclabendazole Resistance (TCBZ-R) in Perú;
- To validate the genetic markers associated with TCBZ-R using independent cohorts and determine whether the genetic basis of resistance is conserved among parasite populations infecting animals and humans
- To define the transcriptional alterations associated with TCBZ-R in Perú.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

Project P10036

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

D43 Chronic non-communicable CVDS and comorbidities in Perú

Research project funded by United States federal funds, under subcontract with Washington University.

For the period from January 1, 2025 to December 31, 2025

Investigator: Hartinger Pena, Stella Maria.

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	113,369
Capital assets	-
Minor assets	976
Materials and supplies	203
Third-party services	21,436
Other management expenses	38,491
Tax expenses	-
Total Direct Costs	174,475
Total Indirect Costs - Overhead	18,043
Total Costs	192,518

Project execution period: From September 2021 to March 2027.

General Objective of the Project: To develop the research careers of fellows in the area of cardiovascular disease, implementation science and environmental exposure; to provide intensive training opportunities and build capacity across a range of scientific disciplines and skills relevant to achieving research independence. The long-term goal of this program is to build a sustainable and collaborative research training infrastructure to develop Peruvian research scientists capable of designing and implementing interventions that address unmet health needs, including the translation of evidence-based interventions and the implementation and dissemination of effective policies to improve public health in Perú.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

Project P10038

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Project of Febrile Illness Surveillance in the Andean and Amazon Countries (Pisaac)

Research project funded by United States federal funds, under direct contract with the National Institute of Health - NIH.

For the period from January 1, 2025 to December 31, 2025

Investigator: Zamudio Fuertes, Carlos Eduardo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	341,692
Capital assets	23,103
Minor assets	226
Materials and supplies	260,028
Third-party services	183,847
Other management expenses	122,740
Tax expenses	2,243
Total Direct Costs	933,879
Total Indirect Costs - Overhead	-
Total Costs	933,879

Project execution period: From September 2021 to August 2026.

General Objective of the Project: To determine the etiology and epidemiology of influenza-like illness and severe acute respiratory illness, with a special focus on COVID-19, in strategically selected regions of Perú and Ecuador; to improve laboratory capacity for disease diagnosis; to produce timely information and accurate surveillance data; and to develop a workforce that can sustain these efforts.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Statistical Methods for Correlated Outcome and Covariate Errors in Studies of HIV/AIDS

Research project funded by United States federal funds, under subcontract with Vanderbilt University Medical Center.

For the period from January 1, 2025 to December 31, 2025

Investigator: Otero Vegas, Larissa.

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	6,648
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	10,090
Other management expenses	-
Tax expenses	-
Total Direct Costs	16,738
Total Indirect Costs - Overhead	1,174
Total Costs	17,912

Project execution period: From January 2019 to April 2026.

General Objective of the Project: To plan the development of a pragmatic clinical trial to evaluate the optimal duration of tuberculosis treatment in HIV-coinfected patients, as well as a reminder pill box, to increase treatment adherence.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Focal mass drug administration (FMDA) to reduce Plasmodium vivax transmission, a pragmatic cluster randomized controlled trial in Perú**Research project funded by United States federal funds, under subcontract with the Regents of the University of California, San Francisco****For the period from January 1, 2025 to December 31, 2025****Investigator: Llanos Cuentas, Elmer Alejandro.**

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	303,331
Capital assets	13,570
Minor assets	6,866
Materials and supplies	54,138
Third-party services	406,475
Other management expenses	370
Tax expenses	7,041
Total Direct Costs	791,791
Total Indirect Costs - Overhead	57,379
Total Costs	849,170

Project execution period: From August 2022 to May 2026.General Objective of the Project: Focal mass drug administration for the elimination of vivax malaria (FLAME): a pragmatic cluster randomized controlled trial in Perú

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

Project P10044

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Training - 2/2 Regional Geohealth Hub Centered in Perú-US

Research project funded by United States federal funds, under subcontract with Emory University

For the period from January 1, 2025 to December 31, 2025

Investigator: Hartinger Pena Stella Maria

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	24,596
Capital assets	1,393
Minor assets	-
Materials and supplies	314
Third-party services	46,639
Other management expenses	68,950
Tax expenses	-
Total Direct Costs	141,892
Total Indirect Costs - Overhead	9,281
Total Costs	151,173

Project execution period: From June 2022 to February 2027.

General Objective of the Project: To strengthen research capacity on topics related to environmental health and the association between ambient air pollution and cardiovascular disease, respiratory disease, COVID-19 and Alzheimer's disease in Perú. To achieve this, annual short courses are offered in Perú, Chile and the United States, along with individual research mentorship and graduate public health programs in Perú. Participant selection will take place in Perú, Bolivia and Ecuador

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

How Land Use Change Transforms The Landscape of Vector-Borne Disease

Research project funded by United States federal funds, under subcontract with The Board of Trustees of the Leland Stanford Junior University

For the period from January 1, 2025 to December 31, 2025

Investigator: Lescano Guevara, Andres Guillermo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	8,691
Capital assets	-
Minor assets	-
Materials and supplies	247
Third-party services	4,672
Other management expenses	-
Tax expenses	(518)
Total Direct Costs	13,092
Total Indirect Costs - Overhead	1,258
Total Costs	14,350

Project execution period: From September 2020 to December 2025.

General Objective of the Project: To determine the presence of zoonotic arboviruses, hantaviruses and arenaviruses in wild arthropods, rodents and bats through active epidemiological surveillance. Wild rodents and bats will be captured in surrounding urban and peri-urban areas during two climatic seasons of the year. Serological, virological and molecular biology tests will be performed for viral diagnosis.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Improving Response to Malaria Outbreaks in Amazon-Basin Countries

Research project funded by United States federal funds,
under subcontract with Duke University.

For the period from January 1, 2025 to December 31, 2025

Investigator: Lescano Guevara, Andres Guillermo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	44,904
Capital assets	-
Minor assets	490
Materials and supplies	4,078
Third-party services	40,170
Other management expenses	-
Tax expenses	-
Total Direct Costs	89,642
Total Indirect Costs - Overhead	8,066
Total Costs	97,708

Project execution period: From September 2021 to August 2026.

General Objective of the Project: Improving knowledge of the distribution of climatic, ecological, social and community factors will enable the optimization of malaria outbreak prediction systems, as well as the timely and effective implementation of public health interventions. Objective: To improve prediction of malaria incidence as part of an early warning system to inform interventions aimed at malaria control.

Methodology: Carried out according to the 2 main specific objectives:

- To assess the relationship between infrastructure, socioeconomic networks and migration across the international border (Brazil-Perú, Ecuador-Perú) with malaria incidence; first, public data will be extracted in order to create a district-level database for the three countries and assess its relationship with malaria. Then, a community network sampling design and a survey for key informants will be designed in two international transport corridors to characterize community networks. Subsequently, malaria transmission patterns across community networks will be assessed, along with whether district-level connectivity predicts these community networks.
- To evaluate scenarios of potential interventions along the borders to jointly reduce malaria; first, communities will be selected and data will be collected. Agent-based models (ABMs) will then be calibrated and validated.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

University of California Global Health Institute Program for Fellows and Scholars

Research project funded by United States federal funds, under subcontract with The Regents of The University of California

For the period from January 1, 2025 to December 31, 2025

Investigator: Lescano Guevara, Andres Guillermo.

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits ⁸	(70)
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	30
Other management expenses	4,500
Tax expenses	-
Total Direct Costs	4,460
Total Indirect Costs - Overhead	106
Total Costs	4,566

Project execution period: From April 2012 to August 2025

General Objective of the Project: Glocal is a program of a consortium of four universities in California, United States of America, funded by the US National Institutes of Health with the objective of providing 12-month mentored research internships in Perú for North American or Peruvian researchers.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

Project P10061

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Genomic Epidemiology of Campylobacter to Improve Disease Control in Low and Middle Income Countries

Research project funded by United States federal funds, under subcontract with The Rector and Visitors of the University of Virginia

For the period from January 1, 2025 to December 31, 2025

Investigator: Schiaffino Salazar, Francesca

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	27,666
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	480
Other management expenses	-
Tax expenses	-
Total Direct Costs	28,146
Total Indirect Costs - Overhead	2,001
Total Costs	30,147

Project execution period: From March 2023 to March 2026

General Objective of the Project: Our central hypothesis is that industrially produced meat products are the main source of campylobacteriosis and of multidrug-resistant *Campylobacter* (MDR) in humans within this population. To test our central hypothesis, we propose to:

- To identify the characteristics of *Campylobacter* associated with specific hosts from zoonotic sources in Perú.
- To characterize the genomes of *Campylobacter* strains causing disease in humans, assess the risk of person-to-person transmission within the household, and identify the microbial genomic characteristics associated with persistent, asymptomatic human carriage.
- To estimate the burden of campylobacteriosis and of human infections by MDR strains attributable to domestic and industrial zoonotic sources.

The proposed project will bring together a highly complementary group of leading researchers with expertise in epidemiology, genomics of *Campylobacter*, bioinformatics and microbial ecology, with the objective of providing information to design strategic, targeted interventions for the control of diseases caused by *Campylobacter*.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Using Burden of Treatment as a Clinical Indicator of Barriers to Multimorbidity Management in Perú: A Mixed Methods Approach

Research project funded by United States federal funds, under contract with the National Institute of Health - NIH.

For the period from January 1, 2025 to December 31, 2025

Investigator: Cuba Fuentes, Maria Sofia

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	9,953
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	35
Other management expenses	-
Tax expenses	-
Total Direct Costs	9,988
Total Indirect Costs - Overhead	3,934
Total Costs	13,922

Project execution period: From September 2020 to September 2025

General Objective of the Project: The Treatment Burden Questionnaire (TBQ) will be used to assess BOT in patients with multimorbidity in Perú. Semi-structured interviews will also be conducted. Participants will be recruited from a variety of clinical and geographic settings. The TBQ will be applied to measure total BOT, as well as BOT related to different dimensions of healthcare workload. Sociodemographic characteristics and other clinical outcome indicators will also be assessed. By collecting this information, we hope to better understand which patient-reported barriers to multimorbidity management exist in Perú and which patient subgroups, particularly those in different healthcare sectors and geographic settings, are at greater risk of experiencing high BOT.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Perú Infectious Diseases Epidemiology Research Training Consortium

Research project funded by United States federal funds, under contract with the National Institute of Health - NIH.

For the period from January 1, 2025 to December 31, 2025

Investigator: Lescano Guevara, Andres Guillermo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	91,654
Capital assets	-
Minor assets	-
Materials and supplies	3,016
Third-party services	22,772
Other management expenses	16,628
Tax expenses	-
Total Direct Costs	134,070
Total Indirect Costs - Overhead	-
Total Costs	134,070

Project execution period: From April 2015 to May 2026

General Objective of the Project: The concurrent influenza pandemic has highlighted the gaps in knowledge and response capacity for emerging infectious diseases. In the first stage of our award, "Perú Infectious Diseases Epidemiology Research Training Consortium," the NAMRU-6-UPCH-JHBSPH-USUHS consortium has contributed to building sustainable research capacity in Perú. Two master's graduates and one doctoral student have returned to Perú and are studying key epidemiological and ecological aspects of the pandemic and seasonal influenza, and three trainees are finishing their coursework. In addition, we established a nearly self-sustaining, tuition-funded epidemiology master's program in Perú, taught by more than 30 Peruvian/foreign doctoral holders and doctoral candidates, many of whom are funded by NIH research and training grants. We have trained 43 students across two successive cohorts, and students from the first cohort have published 13 articles in peer-reviewed journals within one year of training; significant progress has been achieved, but substantial efforts are still needed.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Genomic Epidemiology of Campylobacter in Poultry to Enable the Effective Control of Human Campylobacteriosis in a Middle Income Country

Research project funded by United States federal funds, under contract with the National Institute of Health - NIH.

For the period from January 1, 2025 to December 31, 2025

Investigator: Schiaffino Salazar, Francesca

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	207,558
Capital assets	448
Minor assets	398
Materials and supplies	23,559
Third-party services	8,949
Other management expenses	1,408
Tax expenses	-
Total Direct Costs	242,320
Total Indirect Costs - Overhead	18,240
Total Costs	260,560

Project execution period: From August 2022 to June 2027

General Objective of the Project: This project will investigate the genomic diversity of colonization by multidrug-resistant (MDR) *Campylobacter* in chickens. This will be carried out with the overall objective of reducing the burden of MDR *Campylobacter* in human populations, through adequate control of campylobacteriosis in poultry production and food processing.

We believe there are sufficient genomic characteristics to identify distinct populations of *Campylobacter* among small-scale and industrially produced poultry products, which may significantly contribute to models attributing the origin of disease in humans.

We need to go beyond risk-factor epidemiology in a setting that harbors virtually unlimited sources of *Campylobacter*, in order to effectively identify opportunities for disease control strategies and interventions in both avian and human hosts, so as to reduce the burden of human campylobacteriosis.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Using the Mycobacterium Tuberculosis Genome to Predict Tuberculosis Pathology, Drug Resistance Acquisition and Identify Community Transmission Sites

Research project funded by United States federal funds, under subcontract with The Johns Hopkins University

For the period from January 1, 2025 to December 31, 2025

Investigator: Zimic Peralta, Mirko Juan

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	218
Capital assets	-
Minor assets	-
Materials and supplies	578
Third-party services	39
Other management expenses	-
Tax expenses	(514)
Total Direct Costs	321
Total Indirect Costs - Overhead	7,945
Total Costs	8,266

Project execution period: From April 2021 to March 2026

General Objective of the Project: To combine population-level tuberculosis (TB) pathogen genome sequencing data with radiological data and determine the bacterial genomic basis of TB pathology in Perú at the population level over 20 years, and to phylogenetically infer which genetic backgrounds are associated with the acquisition of drug resistance; then to confirm these findings in the laboratory and in a similar collection of Moldovan datasets of >3000 strains.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Infectious Diseases Training Program in Bolivia: South-South Training with Perú

Research project funded by United States federal funds, under subcontract with The Johns Hopkins University

For the period from January 1, 2025 to December 31, 2025

Investigator: Garcia Lescano, Hector Hugo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	361
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	66
Other management expenses	-
Tax expenses	-
Total Direct Costs	427
Total Indirect Costs - Overhead	2,816
Total Costs	3,243

Project execution period: From May 2015 to May 2025

General Objective of the Project: In this application, we propose to continue our training program to achieve a critical mass of researchers in Bolivia, where we are building local expertise. We will employ a successful stepwise, progressive method to select and train young researchers in Bolivia. This tiered training method allows for candidate selection at multiple levels and ensures that we invest in the most highly qualified and motivated individuals. Bolivia's proximity to Perú gives us a unique opportunity to leverage the human capacity and infrastructure we have built in Perú over the past 25 years, using a South-South training approach to begin building a scientific research community in a more cost-effective manner.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Understanding Immune Modulation in *Taenia Solium* Neurocysticercosis by Using a Novel Postoncosphere In Vitro Model

Research project funded by United States federal funds, under contract with **National Institute of Health - NIH.**

For the period from January 1, 2025 to December 31, 2025

Investigator: Verastegui Pimentel, Manuela Renee

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	32,760
Capital assets	-
Minor assets	-
Materials and supplies	11,650
Third-party services	12,401
Other management expenses	-
Tax expenses	-
Total Direct Costs	56,811
Total Indirect Costs - Overhead	10,504
Total Costs	67,315

Project execution period: From May 2020 to April 2026

General Objective of the Project: A novel in vitro model of *Taenia solium* embryo development, developed by the group, is proposed, which allows the stage-specific differences in antigen expression to be determined in order to identify the immunomodulatory molecules used by the parasite to survive by evading the host's immune response, with a focus on the recently described TGF-ss mimic molecules that have been shown to play a significant role in the parasite's immunomodulation.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Alternative Therapeutic Approaches for the Control of Brain Inflammation Secondary to Antihelminthic Therapy in Neurocysticercosis Using a Novel Experimental Pig Model

Research project funded by United States federal funds, under contract with **National Institute of Health - NIH.**

For the period from January 1, 2025 to December 31, 2025

Investigator: Arroyo Hurtado, Gianfranco

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	68
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	-
Other management expenses	-
Tax expenses	-
Total Direct Costs	68
Total Indirect Costs - Overhead	4,596
Total Costs	4,664

Project execution period: From March 2019 to February 2026

General Objective of the Project: To optimize this animal model and characterize the immunopathological processes associated with CNS cystic infection (study 1). Subsequently, and in conjunction with a combined antihelminthic regimen of albendazole and praziquantel, the model will be used to determine the appropriate doses of ETN (study 2a) or MTX (study 2b) in controlling the local acute inflammatory response resulting from antihelminthic therapy in pigs with viable cerebral cysticercosis; measured outcomes will include inflammatory markers, blood-brain barrier dysfunction/permeability, neuronal damage and structural changes in brain tissue. Finally, in study 3, we will compare the optimal dose of ETN or MTX versus the standard anti-inflammatory regimen using the corticosteroid dexamethasone, in controlling pericystic inflammation using the same endpoints as studies 2a and 2b. We expect our findings to provide the evidentiary basis for further research with ETN or MTX in controlled studies in patients with NCC.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Training in Infectious Diseases in Perú - Time for Implementation Research

Research project funded by United States federal funds, under contract with **National Institute of Health - NIH**.

For the period from January 1, 2025 to December 31, 2025

Investigator: Garcia Lescano, Hector Hugo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	99,605
Capital assets	2,330
Minor assets	620
Materials and supplies	15,982
Third-party services	74,725
Other management expenses	184,359
Tax expenses	1
Total Direct Costs	377,622
Total Indirect Costs - Overhead	18,372
Total Costs	395,994

Project execution period: From July 2001 to February 2027

General Objective of the Project: Training in infectious diseases is essential for building research infrastructure in Perú, so that locally important infectious diseases can be studied. This training grant builds on a long-standing, successful NIH-funded training and research collaboration between Universidad Peruana Cayetano Heredia (UPCH) in Lima, Perú, and the Johns Hopkins School of Public Health (JHSPH). We will develop and train students in short-term, medium-term and long-term programs, both abroad and in Perú.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Ictus: Interdisciplinary Cerebrovascular Diseases Training Program in South America

Research project funded by United States federal funds, under subcontract with University of Washington

For the period from January 1, 2025 to December 31, 2025

Investigator: Garcia Lescano, Hector Hugo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	37,249
Capital assets	2,350
Minor assets	-
Materials and supplies	52
Third-party services	26,500
Other management expenses	16,267
Tax expenses	-
Total Direct Costs	82,418
Total Indirect Costs - Overhead	8,515
Total Costs	90,933

Project execution period: From June 2019 to May 2026

General Objective of the Project: To continue building a cadre of Peruvian physicians to reduce the mortality and morbidity of cerebrovascular disease in Perú. To improve research on the management of cerebrovascular disease and post-stroke rehabilitation in Perú through workshops, didactic courses and master's-level training in research methodology with preceptorships for young Peruvian physicians. To support clinical research projects with mentors in Perú so that all medium- and long-term trainee physicians obtain data for theses, publications and future grant applications in the fields of cerebrovascular rehabilitation and post-stroke care. To improve the quality of stroke care and post-stroke rehabilitation in Perú through implementation science.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Controlled, Randomized, Multicenter Clinical Trial of Single- and Multiple-Dose Regimens of Oxfendazole.

Research project funded by United States federal funds, under contract with the National Institute of Health - NIH.

For the period from January 1, 2025 to December 31, 2025

Investigator: Garcia Lescano, Hector Hugo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	118,001
Capital assets	2,012
Minor assets	2,735
Materials and supplies	2,922
Third-party services	19,091
Other management expenses	-
Tax expenses	133
Total Direct Costs	144,894
Total Indirect Costs - Overhead	9,839
Total Costs	154,733

Project execution period: From September 2023 to May 2028

General Objective of the Project: To compare the efficacy and safety of a single-dose regimen of 20 mg/kg of oxfendazole and a regimen of three similar doses over seven days (day 1, day 4 and day 7), against the most effective available antiparasitic regimen, combined albendazole plus praziquantel over ten days, in individuals with mild NCC (with one to two lesions). The study cohort will also allow the identification of early imaging markers that predict lesion resolution, as well as factors associated with residual calcification or focal gliosis after lesion resolution

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Acceptability, Feasibility, and Preliminary Impact of a Web-Based, HIV Prevention Toolkit with Cisgender Male Couples in Lima, Perú

Research project funded by United States federal funds, under subcontract with The Florida International University Board of Trustees

For the period from January 1, 2025 to December 31, 2025

Investigator: Silva Santisteban Portella, Alfonso Alberto

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	18,961
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	1,211
Other management expenses	-
Tax expenses	-
Total Direct Costs	20,172
Total Indirect Costs - Overhead	4,064
Total Costs	24,236

Project execution period: From July 2021 to June 2026

General Objective of the Project: To test an intervention for gay male couples to determine whether it helps them prevent HIV/STIs. The intervention is a website with 5 modules designed for gay couples

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis

Research project funded by United States federal funds, under subcontract with University of Southern California

For the period from January 1, 2025 to December 31, 2025

Investigator: Caceres Palacios, Carlos Fernando

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	4,078
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	7,784
Other management expenses	-
Tax expenses	-
Total Direct Costs	11,862
Total Indirect Costs - Overhead	2,296
Total Costs	14,158

Project execution period: From July 2021 to June 2026

General Objective of the Project: To evaluate the efficacy of Cefixime in the treatment of early Syphilis compared with Benzathine Penicillin G, and to determine predictive factors for treatment failure among participants.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Fend for TB**

Research project funded by United States federal funds, under subcontract with Rutgers The State University of New Jersey

For the period from January 1, 2025 to December 31, 2025

Investigator: Zamudio Fuertes, Carlos Eduardo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	48,719
Capital assets	-
Minor assets	-
Materials and supplies	2,213
Third-party services	8,095
Other management expenses	-
Tax expenses	376
Total Direct Costs	59,403
Total Indirect Costs - Overhead	7,196
Total Costs	66,599

Project execution period: From June 2020 to June 2026

General Objective of the Project: To support proof-of-concept studies to evaluate new diagnostic tests, assays and strategies for detecting tuberculosis (TB) at early stages of development. Also, to provide feedback to developers on the performance of these technologies and on possible strategies for their implementation in high-tuberculosis-burden settings.

In the context of this initiative, an "early stage" diagnostic refers to a test whose prototype has already been developed and is available for evaluation, but which is not yet routinely used in clinical care or in tuberculosis-related treatment decision-making.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole

Research project funded by United States federal funds, under contract with **National Institute of Health - NIH**.

For the period from January 1, 2025 to December 31, 2025

Investigator: Garcia Lescano, Hector Hugo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	82,202
Capital assets	19,492
Minor assets	1,572
Materials and supplies	72
Third-party services	19,988
Other management expenses	57,318
Tax expenses	-
Total Direct Costs	180,645
Total Indirect Costs - Overhead	13,564
Total Costs	194,209

Project execution period: From August 2023 to July 2028

General Objective of the Project: Our group has extensive experience in the use of oxfendazole (OXF) through studies on cysticercosis caused by *Taenia solium*. Preliminary studies conducted in naturally infected animals have shown that OXF is also highly effective against *Fasciola hepatica*. To date, toxicology studies in animals and phase I studies in humans have been completed, confirming its high bioavailability and, in particular, its safety.

These results suggest that OXF is an excellent candidate for the treatment of human fascioliasis. The study will compare two OXF treatment regimens: a single dose of 20 mg/kg and two doses of 20 mg/kg, versus the standard treatment with triclabendazole (TCBZ), consisting of two doses of 10 mg/kg, in children and adults with chronic infection by *Fasciola hepatica*.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Longitudinal Analysis of Immune Signatures (IMS) of T Cells Specific to *M. tuberculosis*

Research project funded by United States federal funds, under contract with La Jolla Institute for Immunology

For the period from January 1, 2025 to December 31, 2025

Investigator: Mendez Aranda, Melissa Marlene

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	16,053
Capital assets	-
Minor assets	84
Materials and supplies	1,718
Third-party services	4,191
Other management expenses	540
Tax expenses	-
Total Direct Costs	22,586
Total Indirect Costs - Overhead	4,566
Total Costs	27,152

Project execution period: From June 2022 to May 2027

General Objective of the Project: Objective 1) active disease, characterized by uncontained symptomatic MTB infection; Objective 2) reactive MTB (also known as "latent"), characterized by immune reactivity to MTB but without symptoms of disease; and Objective 3) adult BCG (re)vaccination. For persons with active disease, we will conduct longitudinal follow-up of the IMS during the course of treatment and identify markers that predict treatment outcomes. Similarly, we will follow the IMS of "latent" individuals treated prophylactically to determine who is most likely to benefit from treatment. For a separate cohort of latent individuals, we will obtain antigen-specific lung-resident T cells and use them to compare the IMS between blood and lung T cells. Finally, we will compare pre- and post-BCG vaccination samples in adults, which has been shown to protect against disease, to characterize the associated vaccine-induced IMS. Overall, our proposal will generate longitudinal immune profiles of MTB-specific T cells that will allow us to compare and contrast how different exposure settings affect the observed IMS. This will advance basic understanding of T cell responses to MTB, and has potential applications for the development of diagnostic or prognostic tests, as well as vaccines.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****An Immune System for the City: A New Paradigm for Control of Urban Disease Vectors**

Research project funded by United States federal funds, under subcontract with University of Pennsylvania

For the period from January 1, 2025 to December 31, 2025

Investigator: Paz Soldan Parlette, Valerie Andrea

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	15,534
Capital assets	-
Minor assets	-
Materials and supplies	45
Third-party services	3,627
Other management expenses	-
Tax expenses	-
Total Direct Costs	19,206
Total Indirect Costs - Overhead	11,071
Total Costs	30,277

Project execution period: From July 2019 to May 2026

General Objective of the Project: To develop a new paradigm for the control of dangerous insects modeled on the adaptive immune system. The project will adapt aspects of the immune system from the cellular scale to the landscape scale, and will test the new approach against a conventional one using a cluster-randomized design within an ongoing Chagas disease vector control program in the city of Arequipa, Perú.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Multidisciplinary Training Program on Neuropsychiatry and Behavioral Disorders in First Nations (NEUFIN)

Research project funded by United States federal funds, under subcontract with University of Texas Health Science Center at San Antonio

For the period from January 1, 2025 to December 31, 2025

Investigator: Gallo Lopez-Aliaga, Carla Maria

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	27,795
Capital assets	-
Minor assets	-
Materials and supplies	915
Third-party services	20,675
Other management expenses	64,359
Tax expenses	-
Total Direct Costs	113,744
Total Indirect Costs - Overhead	-
Total Costs	113,744

Project execution period: From September 2021 to July 2026

General Objective of the Project: We will continue to strengthen the capabilities and train Quechua neuroscientists in clinical research applications related to neuroimaging, genetics, epidemiology, neuropsychology and neuromodulation. We will also create personalized training environments and an online innovation ecosystem to support capacity building and professional development for Quechua neuroscientists after completing their initial academic training.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Research Training in Chronic, Non-Communicable Respiratory Diseases in Perú**

Research project funded by United States federal funds, under subcontract with The Johns Hopkins University

For the period from January 1, 2025 to December 31, 2025

Investigator: Hartinger Pena, Stella Maria

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	(209)
Capital assets	3,150
Minor assets	822
Materials and supplies	2,427
Third-party services	6,671
Other management expenses	75,604
Tax expenses	-
Total Direct Costs	88,465
Total Indirect Costs - Overhead	4,698
Total Costs	93,163

Project execution period: From April 2020 to November 2025

General Objective of the Project: To provide intensive training opportunities across a range of scientific disciplines relevant to the areas of environmental exposure and chronic and infectious lung disease. In addition, PulmPerú is focused on generating high global-impact evidence, applying rigorous methodologies to generate innovative, high-quality health research in Perú together with young researchers.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Spatially Responsive Mass Vaccination Strategies for Urban Rabies**

Research project funded by United States federal funds, under subcontract with University of Pennsylvania

For the period from January 1, 2025 to December 31, 2025

Investigator: Paz Soldan Parlette, Valerie Andrea

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	159,032
Capital assets	-
Minor assets	-
Materials and supplies	328
Third-party services	20,932
Other management expenses	-
Tax expenses	-
Total Direct Costs	180,292
Total Indirect Costs - Overhead	13,327
Total Costs	193,619

Project execution period: From April 2022 to March 2027

General Objective of the Project: To develop and test new algorithms to optimize the location of canine vaccination sites so as not to generate long lines. The coverage and reach of a new vaccination strategy, incorporating spatial optimization and queuing theory, will be compared to current practice; we will also develop data-driven methods to reach underserved populations through gamified door-to-door campaigns, as well as a fixed-point campaign. Finally, we will assess the acceptability, scalability and portability of a new spatially responsive vaccination approach.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Improving National Knowledge and Awareness of Fungal Infections in Perú**

Research project funded by United States federal funds, under contract with **National Institute of Health - NIH**.

For the period from January 1, 2025 to December 31, 2025

Investigator: Banda Flores, Claudia Lizette

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	106,590
Capital assets	1,500
Minor assets	900
Materials and supplies	29,433
Third-party services	95,689
Other management expenses	3,653
Tax expenses	-
Total Direct Costs	237,765
Total Indirect Costs - Overhead	32,945
Total Costs	270,710

Project execution period: From September 2021 to September 2026

General Objective of the Project: The objective of this project is to strengthen human capacity, increase knowledge and awareness, and improve the appropriate diagnosis of fungal infections in Perú.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Program for Advanced Research Capacities for AIDS in Perú (PARACAS) Harnessing Implementation Science**

Research project funded by United States federal funds, under contract with **National Institute of Health - NIH**.

For the period from January 1, 2025 to December 31, 2025

Investigator: Gotuzzo Herencia, Jose Eduardo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	21,458
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	43,730
Other management expenses	103,894
Tax expenses	-
Total Direct Costs	169,082
Total Indirect Costs - Overhead	-
Total Costs	169,082

Project execution period: From June 2020 to March 2026

General Objective of the Project: PARACAS will strengthen mentored research training in Implementation Science at the doctoral level for outstanding young health researchers and mid-career professionals. This will enable them to design and evaluate effective interventions tailored to the local health context.

This program will help consolidate a specialized Peruvian scientific workforce committed to HIV research, needed to advance toward an AIDS-free generation.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES
CCASANET 2021 - 2026**

Research project funded by United States federal funds, under contract with The Caribbean, Central and South America Network for HIV Epidemiology

For the period from January 1, 2025 to December 31, 2025

Investigator: Gotuzzo Herencia, Jose Eduardo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	41,546
Capital assets	3,827
Minor assets	53
Materials and supplies	3,068
Third-party services	34,306
Other management expenses	588
Tax expenses	359
Total Direct Costs	83,747
Total Indirect Costs - Overhead	8,957
Total Costs	92,704

Project execution period: From July 2021 to June 2026

General Objective of the Project: CCASAnet (Caribbean, Central and South America Network for HIV Epidemiology) is a project that creates and maintains a shared HIV database across countries in the Caribbean, Central America and South America. Information collected from various centers and institutions is integrated into a common repository to conduct collaborative research.

The combined data are used to answer questions about the characteristics of the regional HIV epidemic, including patient care, treatment outcomes, disease progression and epidemiological trends in the region.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Addressing Hypertension and Diabetes Through Community-Engaged Systems in Puno, Perú (ANDES Study)**

Research project funded by United States federal funds, under contract with **National Institute of Health - NIH.**

For the period from January 1, 2025 to December 31, 2025

Investigator: Hartinger Pena, Stella Maria

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	109,036
Capital assets	2,598
Minor assets	11,003
Materials and supplies	962
Third-party services	8,494
Other management expenses	932,255
Tax expenses	1,905
Total Direct Costs	1,066,253
Total Indirect Costs - Overhead	11,179
Total Costs	1,077,432

Project execution period: From November 2020 to January 2027

General Objective of the Project: To design and evaluate the effectiveness of a multi-component strategy for the diagnosis and treatment of hypertension (HTN) and type 2 diabetes (T2D). The ANDES multi-component strategy consists of 1) health campaigns with events offering community-based HTN/T2D diagnosis and 2) follow-up led by community stakeholders to improve treatment adherence

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Prevention Through Vaccination Training (PREVENT) Program**

Research project funded by United States federal funds, under subcontract with Vanderbilt University Medical Center

For the period from January 1, 2025 to December 31, 2025

Investigator: Ochoa Woodell, Theresa Jean

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	29,129
Capital assets	-
Minor assets	-
Materials and supplies	26,087
Third-party services	12,489
Other management expenses	21,835
Tax expenses	-
Total Direct Costs	89,540
Total Indirect Costs - Overhead	1,521
Total Costs	91,061

Project execution period: From May 2023 to December 2027

General Objective of the Project: Grant recipients must promote objectivity in research by establishing standards that reasonably ensure that the design, conduct and reporting of NIH-funded research are free from bias arising from investigators' financial conflicts of interest (FCOI), in accordance with the 2011 revised regulation set forth in Title 42 of the Code of Federal Regulations (CFR), Part 50, Subpart F.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Isolation and Identification of CXCR4 and CXCR7 Agonists from Traditior
Phytopharmaceuticals as Potential Novel Drugs for Mental Disorders

Research project funded by United States federal funds, under contract with **National Institute of Health - NIH.**

For the period from January 1, 2025 to December 31, 2025

Investigator: Gallo Lopez-Aliaga, Carla Maria

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	26,718
Capital assets	3,714
Minor assets	343
Materials and supplies	9,687
Third-party services	35,918
Other management expenses	707
Tax expenses	-
Total Direct Costs	77,087
Total Indirect Costs - Overhead	11,949
Total Costs	89,036

Project execution period: From August 2020 to July 2026

General Objective of the Project: To leverage knowledge from traditional medicine to guide the discovery of molecules that act on novel therapeutic targets and that may improve current treatments for mental disorders, providing better treatment adherence, better long-term outcomes and greater patient functionality.

In addition, the discovery of these molecules could contribute to a better understanding of the biological processes that are not yet fully understood and that are related to the onset of these complex, multifactorial, highly disabling disorders with a significant genetic basis.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Application of Novel Biomarkers to Measure Health Impacts of Anthropogenic Change in the Amazon**

Research project funded by United States federal funds, under subcontract with The Research Foundation for SUNY, University at Albany

For the period from January 1, 2025 to December 31, 2025

Investigator: Bernabe Ortiz, Antonio

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	2,702
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	570
Other management expenses	83
Tax expenses	-
Total Direct Costs	3,355
Total Indirect Costs - Overhead	3,294
Total Costs	6,649

Project execution period: From August 2022 to December 2025

General Objective of the Project: To evaluate changes in adult dietary patterns and cardiometabolic disease risk profiles (HbA1C, HDL-C, LDL-C, height, weight, waist-hip ratio, blood pressure and triglycerides) associated with the construction of the Inter-oceanic Highway (IOH) through the southern Peruvian Amazon, by measuring these biomarkers of the nutritional transition and complementary dietary survey data.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES
Diagnostic Innovations for Pediatric Tuberculosis in Bolivia

Research project funded by United States federal funds, under subcontract with The Administrators of the Tulane Educational Fund (DBA Tulane University)

For the period from January 1, 2025 to December 31, 2025

Investigator: Zimic Peralta, Mirko Juan

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	11,764
Capital assets	-
Minor assets	-
Materials and supplies	27
Third-party services	7,175
Other management expenses	-
Tax expenses	-
Total Direct Costs	18,966
Total Indirect Costs - Overhead	2,891
Total Costs	21,857

Project execution period: From June 2023 to May 2026

General Objective of the Project: Our objective is to directly address the diagnostic challenges of childhood tuberculosis with paucibacillary disease by applying innovative, highly sensitive techniques to detect cell-free DNA from *Mycobacterium tuberculosis* (cfDNA) in peripheral blood samples of children with suspected tuberculosis.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****South American Program in HIV Prevention Research (SAPHIR)**

Research project funded by United States federal funds, under subcontract with The Regents of the University of California

For the period from January 1, 2025 to December 31, 2025

Investigator: Carcamo Cavagnaro, Cesar Paul Eugenio

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	3,530
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	7,535
Other management expenses	-
Tax expenses	-
Total Direct Costs	11,065
Total Indirect Costs - Overhead	1,600
Total Costs	12,665

Project execution period: From June 2021 to May 2026

General Objective of the Project: To provide developing researchers from the United States with a structured education and training program based on a research theme focused on the field of HIV prevention in Latin America.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Integrated Next-Generation Surveillance in Global Health: Translation to Action (Insight to Action)

Research project funded by United States federal funds, under subcontract with University of Washington

For the period from January 1, 2025 to December 31, 2025

Investigator: Carcamo Cavagnaro, Cesar Paul Eugenio

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	109,769
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	90
Other management expenses	-
Tax expenses	-
Total Direct Costs	109,859
Total Indirect Costs - Overhead	28,398
Total Costs	138,257

Project execution period: From January 2022 to November 2025

General Objective of the Project: To maintain GTT processes and stakeholder engagement in Perú (interoperability). To conduct trainings and workshops and provide technical assistance in the region. To contribute to regional R training and communities of practice. To work with the University of Washington and other partners to support the launch of regional programs.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Expanding the Toolbox for the Prevention of Sarcopenia and Osteoporosis in Peruvians Aging with HIV: A Validation Study

Research project funded by United States federal funds, under subcontract with Yale University

For the period from January 1, 2025 to December 31, 2025

Investigator: Garcia Funegra, Patricia Jannet

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	6,957
Capital assets	2,050
Minor assets	-
Materials and supplies	713
Third-party services	43,124
Other management expenses	16,734
Tax expenses	-
Total Direct Costs	69,578
Total Indirect Costs - Overhead	2,902
Total Costs	72,480

Project execution period: From July 2022 to June 2027

General Objective of the Project: To explore the validity of three brief sarcopenia and osteoporosis screening tools that have been used in primary care settings in other countries for the general population.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

**Improving the Diagnosis of HIV-Associated Neurocognitive Disorder (HAND) in Latin America:
A Multimodal Approach to HAND in Perú**

Research project funded by United States federal funds, under subcontract with The University of North Carolina at Chapel Hill

For the period from January 1, 2025 to December 31, 2025

Investigator: Garcia Funegra, Patricia Jannet

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	30,354
Capital assets	-
Minor assets	-
Materials and supplies	5,660
Third-party services	11,031
Other management expenses	-
Tax expenses	240
Total Direct Costs	47,285
Total Indirect Costs - Overhead	10,058
Total Costs	57,343

Project execution period: From July 2022 to November 2025

General Objective of the Project: To determine whether a multimodal screening platform improves the diagnosis and prediction of HAND in Perú. To determine whether a tablet-based neuropsychological tool, adapted and validated for HAND screening in Perú, performs comparably to the paper-and-pencil NP test battery in PLWH at a health center in Lima, Perú. To determine whether a predictive model that assigns individual-level HAND risk can predict HAND with high certainty in Perú.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Next-Generation Sequencing Diagnostics to Identify Etiologies of Acute Undifferentiated Fever in the Peruvian Amazon

Research project funded by United States federal funds, under contract with RTI International

For the period from January 1, 2025 to December 31, 2025

Investigator: Falconi Agapito, Francesca

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	9,361
Capital assets	-
Minor assets	242
Materials and supplies	-
Third-party services	165
Other management expenses	-
Tax expenses	-
Total Direct Costs	9,768
Total Indirect Costs - Overhead	4,556
Total Costs	14,324

Project execution period: From May 2023 to November 2025

General Objective of the Project: To implement metagenomic sequencing on the Oxford Nanopore MinION platform and assess the potential impact of this technology on standard clinical diagnosis

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

Project P10319

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

CooperaSalud II: Technical Assistance to Strengthen Post-Pandemic HIV Prevention and Control Capacities in the Peruvian Armed Forces

Research project funded by United States federal funds, under contract with Navsup Fleet Logistics Support Center Sigonella

For the period from January 1, 2025 to December 31, 2025

Investigator: Caceres Palacios, Carlos Fernando

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	222,675
Capital assets	19,034
Minor assets	8,538
Materials and supplies	64,007
Third-party services	156,748
Other management expenses	2,619
Tax expenses	-
Total Direct Costs	473,621
Total Indirect Costs - Overhead	56,088
Total Costs	529,709

Project execution period: From September 2023 to September 2027

General Objective of the Project: To provide technical assistance to the Peruvian Armed Forces to improve their HIV prevention and control capacities, under the U=U (Undetectable = Untransmittable) paradigm.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients

Research project funded by United States federal funds, under contract with Kephera Diagnostics, LLC

For the period from January 1, 2025 to December 31, 2025

Investigator: Garcia Lescano, Hector Hugo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	43,487
Capital assets	-
Minor assets	-
Materials and supplies	288
Third-party services	2,407
Other management expenses	-
Tax expenses	-
Total Direct Costs	46,182
Total Indirect Costs - Overhead	3,164
Total Costs	49,346

Project execution period: From May 2023 to April 2027

General Objective of the Project: In Phase I of this project, Kephera Inc. used recombinant and synthetic antigens of *Taenia solium* equivalent to those used in the EITB test (*Enzyme-Linked Immunoelctrotransfer Blot*), one of the reference tests for the diagnosis of cysticercosis.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Enabling Infectious Disease Research Capacity in the Peruvian Amazon**

Research project funded by United States federal funds, under subcontract with The Rector and Visitors of the University of Virginia

For the period from January 1, 2025 to December 31, 2025

Investigator: Schiaffino Salazar, Francesca

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	15,638
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	1,421
Other management expenses	-
Tax expenses	-
Total Direct Costs	17,059
Total Indirect Costs - Overhead	86
Total Costs	17,145

Project execution period: From March 2023 to February 2026

General Objective of the Project: To improve training and the professional base for infectious disease research in Iquitos, based at the National University of the Peruvian Amazon

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

An Integrated Approach to Understand and Diagnose Congenital Chagas Disease

Research project funded by United States federal funds, under subcontract with The University of North Carolina at Chapel Hill

For the period from January 1, 2025 to December 31, 2025

Investigator: Zimic Peralta, Mirko Juan

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	12,636
Capital assets	-
Minor assets	2,153
Materials and supplies	5,637
Third-party services	5,254
Other management expenses	-
Tax expenses	350
Total Direct Costs	26,030
Total Indirect Costs - Overhead	4,878
Total Costs	30,908

Project execution period: From June 2022 to November 2025

General Objective of the Project: Our long-term objective is to improve understanding of the maternal and parasite factors that influence the vertical transmission of *Trypanosoma cruzi* and develop better diagnostic tests for congenital Chagas disease.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Improvising HIV and STI Prevention and Care for Venezuelan Sexual and Gender Minority Migrants in Lima, Perú**

Research project funded by United States federal funds, under contract with **National Institute of Health - NIH**.

For the period from January 1, 2025 to December 31, 2025

Investigator: Silva Santisteban Portella, Alfonso Alberto

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	92,232
Capital assets	11,150
Minor assets	845
Materials and supplies	6,213
Third-party services	8,649
Other management expenses	49,815
Tax expenses	-
Total Direct Costs	168,904
Total Indirect Costs - Overhead	12,942
Total Costs	181,846

Project execution period: From September 2023 to January 2026

General Objective of the Project: Will collect qualitative data from focus groups and interviews with Venezuelan sexual and gender minorities to identify their unique vulnerabilities to HIV and other related STIs

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Integration of Smartphone Photography for Trachoma Assessment, Visual Acuity, and Mobile Autorefraction to Improve Community Public Health Monitoring

Research project funded by United States federal funds, under subcontract with The Regents of the University of California, San Francisco

For the period from January 1, 2025 to December 31, 2025

Investigator: Lescano Guevara, Andres Guillermo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	59,794
Capital assets	-
Minor assets	-
Materials and supplies	2,739
Third-party services	62,729
Other management expenses	-
Tax expenses	-
Total Direct Costs	125,262
Total Indirect Costs - Overhead	14,406
Total Costs	139,668

Project execution period: From September 2023 to August 2026

General Objective of the Project: To assess the feasibility of a mobile application that integrates the Cellscope and other functionalities on the Tropical Data platform using different types of smartphones, under a variety of conditions.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****UJMT Launch: Training the Next Generation of Leaders in Global Health Research**

Research project funded by United States federal funds, under subcontract with The University of North Carolina at Chapel Hill

For the period from January 1, 2025 to December 31, 2025

Investigator: Lescano Guevara, Andres Guillermo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	2,894
Capital assets	-
Minor assets	-
Materials and supplies	136
Third-party services	260
Other management expenses	-
Tax expenses	-
Total Direct Costs	3,290
Total Indirect Costs - Overhead	576
Total Costs	3,866

Project execution period: From July 2023 to September 2025

General Objective of the Project: Structural causes of epilepsy (tumors, strokes, etc.) and central nervous system infections (such as neurocysticercosis) that lead to hippocampal sclerosis are predicted

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES**
Research Ethics Training in Latin America (RETAMA)

Research project funded by United States federal funds, under subcontract with **National Institute of Health - NIH.**

For the period from January 1, 2025 to December 31, 2025

Investigator: Ochoa Woodell, Theresa Jean

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	107,822
Capital assets	-
Minor assets	-
Materials and supplies	209
Third-party services	9,769
Other management expenses	140,099
Tax expenses	-
Total Direct Costs	257,899
Total Indirect Costs - Overhead	2,354
Total Costs	260,253

Project execution period: From April 2024 to March 2029

General Objective of the Project: To increase the impact of high-quality, responsibly conducted research in health and health sciences

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Understanding Host-Pathogen Interactions in Patients with Syphilis Infection**

Research project funded by United States federal funds, under subcontract with University of Southern California

For the period from January 1, 2025 to December 31, 2025

Investigator: Caceres Palacios, Carlos Fernando

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	167,685
Capital assets	10,216
Minor assets	-
Materials and supplies	70,102
Third-party services	51,649
Other management expenses	164
Tax expenses	218
Total Direct Costs	300,034
Total Indirect Costs - Overhead	13,893
Total Costs	313,927

Project execution period: From December 2023 to October 2026

General Objective of the Project: The study will recruit, treat and follow individuals with incident syphilis without prior infection (with documentation of recent seronegative TP) and individuals with repeat syphilis infection (with documentation of prior seropositive TP). We will compare response markers.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Aphasia Rehabilitation in Perú: Current Clinical Care, Facilitators and Barriers to Achieving Best Clinical Practice

Research project funded by United States federal funds, under subcontract with Harvard T.H. Chan School of Public Health

For the period from January 1, 2025 to December 31, 2025

Investigator: Garcia Funegra, Patricia Jannet

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	88
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	-
Other management expenses	-
Tax expenses	-
Total Direct Costs	88
Total Indirect Costs - Overhead	201
Total Costs	289

Project execution period: From July 2023 to July 2025

General Objective of the Project: To characterize usual aphasia care in Perú and identify barriers and facilitators to ideal aphasia clinical practice in Perú.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

UJMT Launch: Training the Next Generation of Leaders in Global Health Research - UJMT D43 Training Program ANDES Trainee

Research project funded by United States federal funds, under subcontract with The University of North Carolina at Chapel Hill

For the period from January 1, 2025 to December 31, 2025

Investigator: Lescano Guevara, Andres Guillermo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	-
Capital assets	-
Minor assets	-
Materials and supplies	97
Third-party services	239
Other management expenses	3,240
Tax expenses	-
Total Direct Costs	3,576
Total Indirect Costs - Overhead	248
Total Costs	3,824

Project execution period: From July 2023 to September 2025

General Objective of the Project: The program's objectives are to strengthen research capacity in low- and middle-income countries (LMICs), particularly by training the next generation of clinical researchers, strengthening global health research capacity, and fostering international research.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Research Training in Integration of Epidemiology and Implementation Science for Neglected Zoonotic Disease Control in Perú**

Research project funded by United States federal funds, under contract with **National Institute of Health - NIH**.

For the period from January 1, 2025 to December 31, 2025

Investigator: Bustos Palomino, Javier Arturo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	38,470
Capital assets	19,903
Minor assets	-
Materials and supplies	841
Third-party services	23,446
Other management expenses	55,868
Tax expenses	1,532
Total Direct Costs	140,060
Total Indirect Costs - Overhead	9,370
Total Costs	149,430

Project execution period: From April 2024 to March 2026

General Objective of the Project: The mission of this D43 application is to develop and establish in Perú an innovative transdisciplinary training program in implementation science and epidemiology.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

Project P10411

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****UC Davis Multidisciplinary Cancer Research Training Program to Advance Precision Cancer Prevention and Care in Latin America**

Research project funded by United States federal funds, under contract with **National Institute of Health - NIH.**

For the period from January 1, 2025 to December 31, 2025

Investigator: Vidaurre Rojas, Tatiana

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	6,082
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	10
Other management expenses	-
Tax expenses	-
Total Direct Costs	6,092
Total Indirect Costs - Overhead	520
Total Costs	6,612

Project execution period: From September 2022 to August 2027

General Objective of the Project: It is expected to contribute to the development of a critical mass of basic scientists, physicians and other health professionals who will drive basic and applied cancer research.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Research project funded by United States federal funds, under subcontract with Yale University

For the period from January 1, 2025 to December 31, 2025

Investigator: Garcia Funegra, Patricia Jannet

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	-
Capital assets	1,720
Minor assets	-
Materials and supplies	396
Third-party services	29,906
Other management expenses	18,096
Tax expenses	-
Total Direct Costs	50,118
Total Indirect Costs - Overhead	4,616
Total Costs	54,734

Project execution period: From July 2024 to March 2026

General Objective of the Project: To determine the prevalence of MSD and disability among PLWH aged 40 years at two tertiary-level HIV programs in Lima, Perú

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Biological Implications of Breast Cancer Protective Variants in Latin American Women with High Indigenous American Ancestry

Research project funded by United States federal funds, under subcontract with The Regents of the University of California

For the period from January 1, 2025 to December 31, 2025

Investigator: Vidaurre Rojas, Tatiana

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	20,334
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	16,210
Other management expenses	-
Tax expenses	-
Total Direct Costs	36,544
Total Indirect Costs - Overhead	2,854
Total Costs	39,398

Project execution period: From July 2023 to October 2025

General Objective of the Project: The objective will be to accelerate participant recruitment to reach a total goal of 3,000 patients in the PEGEN-BC study by the end of the third year of the project's *No-Cost Extension*).

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Perceptions of People Working Along the Device Development Pipeline

Research project funded by United States federal funds, under subcontract with University of Washington

For the period from January 1, 2025 to December 31, 2025

Investigator: Garcia Funegra, Patricia Jannet

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	3,645
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	10
Other management expenses	-
Tax expenses	-
Total Direct Costs	3,655
Total Indirect Costs - Overhead	258
Total Costs	3,913

Project execution period: From July 2024 to March 2026

General Objective of the Project: To Explore the Barriers and Facilitators at the Stages of the Medical Device Development Process to Promote Medical Device Production in Perú

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

Project P10451

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Evaluation of Autoantibodies and Atypical B Cells as Markers of Asymptomatic *P. vivax* Infections in the Amazon

Research project funded by United States federal funds, under subcontract with Yale University

For the period from January 1, 2025 to December 31, 2025

Investigator: Villasis Mayuri, Elizabeth Melissa

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	19,860
Capital assets	-
Minor assets	-
Materials and supplies	1,055
Third-party services	37,826
Other management expenses	289
Tax expenses	405
Total Direct Costs	59,435
Total Indirect Costs - Overhead	4,962
Total Costs	64,397

Project execution period: From July 2024 to August 2025

General Objective of the Project: This proposal aims to understand the underlying pathophysiology of this phenomenon by assessing the presence of autoantibodies and atypical B cells, as well as determining their usefulness as biomarkers.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

Project P10453

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Exploring Intersectional Stigma and Health Outcomes in Older People with HIV (OPWH)**

Research project funded by United States federal funds, under subcontract with Yale University

For the period from January 1, 2025 to December 31, 2025

Investigator: Garcia Funegra, Patricia Jannet

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	-
Capital assets	-
Minor assets	-
Materials and supplies	3,268
Third-party services	30,757
Other management expenses	28,139
Tax expenses	-
Total Direct Costs	62,164
Total Indirect Costs - Overhead	4,892
Total Costs	67,056

Project execution period: From July 2024 to June 2027General Objective of the Project: To Assess How Stigma and Intersectional Stigma Influence Health Outcomes

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****The Indigenous Peoples' Observatory Network (IPON): The Climate-Food-Health Nexus**

Research project funded by United States federal funds, under subcontract with Virginia Polytechnic Institute and State University

For the period from January 1, 2025 to December 31, 2025

Investigator: Zavaleta Cortijo, Claudia Carol

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	-
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	6,587
Other management expenses	-
Tax expenses	-
Total Direct Costs	6,587
Total Indirect Costs - Overhead	658
Total Costs	7,245

Project execution period: From June 2024 to May 2026

General Objective of the Project: The Main Objective of This Study Is to Launch the Indigenous Peoples' Observatory Network (IPON) Across the Global South and North, and in the Seven UN Socio-Cultural Regions.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Metagenomic Characterization of Pathogens and Resistance Genes in Wastewater in Perú

Research project funded by United States federal funds, under subcontract with Harvard T.H. Chan School of Public Health

For the period from January 1, 2025 to December 31, 2025

Investigator: Tsukayama Cisneros, Pablo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	435
Capital assets	3,278
Minor assets	-
Materials and supplies	-
Third-party services	-
Other management expenses	-
Tax expenses	-
Total Direct Costs	3,713
Total Indirect Costs - Overhead	-
Total Costs	3,713

Project execution period: From July 2023 to March 2026

General Objective of the Project: To Support Capacity Building in Low- and Middle-Income Countries (LMICs) and in the United States (US) to Train the Next Generation of Public Health Innovators and Leaders

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Effectively Linking Molecular Informatics and Network Analytics to Reduce Malaria (ELIMINAR-MALARIA)

Research project funded by United States federal funds, under subcontract with Duke University

For the period from January 1, 2025 to December 31, 2025

Investigator: Lescano Guevara, Andres Guillermo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	8,002
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	1,170
Other management expenses	-
Tax expenses	-
Total Direct Costs	9,172
Total Indirect Costs - Overhead	798
Total Costs	9,970

Project execution period: From June 2024 to March 2026

General Objective of the Project: The objective of this proposal is to develop scalable and applicable approaches to measure human mobility in the Amazon. Failure to do so would significantly limit the ability to understand how population movement influences various health, environmental and social outcomes in this region.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****A Global Epidemiology of Cognitive Impairment and Dementia Due to Alzheimer's Disease and Related Disorders: The COSMIC Collaboration**

Research project funded by United States federal funds, under subcontract with The University of New South Wales

For the period from January 1, 2025 to December 31, 2025

Investigator: Miranda Montero, Juan Jaime

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	29,398
Capital assets	-
Minor assets	144
Materials and supplies	3,225
Third-party services	297
Other management expenses	17,755
Tax expenses	-
Total Direct Costs	50,819
Total Indirect Costs - Overhead	3,888
Total Costs	54,707

Project execution period: From September 2023 to August 2025

General Objective of the Project: We plan to examine the role of cerebrovascular disease in dementia across diverse populations using harmonized magnetic resonance imaging data. We will also investigate the diagnostic and monitoring value of disease progression through these tools to improve understanding of the mechanisms contributing to cognitive impairment and dementia.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Long-Term Effects of a Household Air Pollution Intervention: Follow-Up of a Randomized Controlled Trial

Research project funded by United States federal funds, under subcontract with The Johns Hopkins University

For the period from January 1, 2025 to December 31, 2025

Investigator: Hartinger Pena, Stella Maria

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	4,761
Capital assets	1,250
Minor assets	170
Materials and supplies	38
Third-party services	702
Other management expenses	-
Tax expenses	-
Total Direct Costs	6,921
Total Indirect Costs - Overhead	-
Total Costs	6,921

Project execution period: From September 2024 to June 2026

General Objective of the Project: Objective 1: to annually assess children's growth after completion of the HAPIN trial up to nine years of age.

Objective 2: to assess children's cognitive development after completion of the trial.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Lung Ultrasound and Artificial Intelligence Technology for the Diagnosis of Tuberculosis in Low- and Middle-Income Countries

Research project funded by United States federal funds, under subcontract with The Johns Hopkins University

For the period from January 1, 2025 to December 31, 2025

Investigator: Zimic Peralta, Mirko Juan

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	66,027
Capital assets	-
Minor assets	-
Materials and supplies	2,664
Third-party services	13,029
Other management expenses	-
Tax expenses	-
Total Direct Costs	81,720
Total Indirect Costs - Overhead	1,321
Total Costs	83,041

Project execution period: From September 2024 to June 2026

General Objective of the Project: i) To assess the utility of lung ultrasound evaluation for detecting pulmonary tuberculosis.

ii) If ultrasound demonstrates good sensitivity and specificity, to develop tools and strategies that facilitate its implementation as a diagnostic method.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****D43 Research Training Grant: Chronic Non-Communicable CVDs and Co-Morbidities in Perú**

Research project funded by United States federal funds, under contract with **National Institute of Health - NIH**.

For the period from January 1, 2025 to December 31, 2025

Investigator: Hartinger Pena, Stella Maria

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	38,623
Capital assets	746
Minor assets	-
Materials and supplies	3,687
Third-party services	10,832
Other management expenses	30,117
Tax expenses	-
Total Direct Costs	84,005
Total Indirect Costs - Overhead	2,288
Total Costs	86,293

Project execution period: From August 2025 to July 2026

General Objective of the Project: To Develop the Research Careers of Fellows in the Area of Cardiovascular Disease, Implementation Science and Environmental Exposure; To Provide Training Opportunities

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

UNIVERSIDAD PERUANA CAYETANO HEREDIA

STATEMENT OF EXPENDITURES

Effectively Linking Molecular Informatics and Network Analytics to Reduce Malaria (ELIMINAR-MALARIA) - SUNY

Research project funded by United States federal funds, under subcontract with The Research Foundation for SUNY on Behalf of the University at Buffalo

For the period from January 1, 2025 to December 31, 2025

Investigator: Lescano Guevara, Andres Guillermo

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	1,756
Capital assets	-
Minor assets	-
Materials and supplies	-
Third-party services	-
Other management expenses	-
Tax expenses	-
Total Direct Costs	1,756
Total Indirect Costs - Overhead	-
Total Costs	1,756

Project execution period: From June 2025 to May 2026

General Objective of the Project: The objective of this proposal is to develop scalable and applicable approaches to measure human mobility in the Amazon. Failure to do so fundamentally threatens the long-term viability of elimination strategies, since understanding how people move is essential to designing effective interventions, guiding epidemiological surveillance and controlling disease spread.

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

Project P10557

UNIVERSIDAD PERUANA CAYETANO HEREDIA**STATEMENT OF EXPENDITURES****Accuracy of Novel Diagnostic Tests for Detection of Tuberculosis in Adults: FEND for TB**

Research project funded by United States federal funds, under subcontract with Rutgers The State University of New Jersey

For the period from January 1, 2025 to December 31, 2025

Investigator: Espinoza Lopez, Patricia Asuncion

	Project Execution (*)
	US\$
Direct Costs	
Employee benefits	15,610
Capital assets	-
Minor assets	-
Materials and supplies	442
Third-party services	3
Other management expenses	-
Tax expenses	-
Total Direct Costs	16,055
Total Indirect Costs - Overhead	-
Total Costs	16,055

Project execution period: From September 2025 to August 2030

General Objective of the Project: To Provide Biological Samples, as Well as Quality Clinical Information for the FEND for TB Group's TB Research in Order to Assess Diagnostic Accuracy and Characteristics

(*) Covers the audited period, from January 1, 2025 to December 31, 2025.

IV. BACKGROUND AND SCOPE OF WORK

Our engagement was to perform an audit of the expenditures of the Research Projects funded by United States federal funds, for the period from January 1, 2025 to December 31, 2025. The audit consisted of an examination of the Statements of Expenditures of each Research Project, performed in accordance with Generally Accepted Governmental Audit Standards (GAGAS), International Standards on Auditing (ISA) and the Compliance Supplement of the United States Office of Management and Budget (OMB) - Circular A-133. Accordingly, we examined the procedures, standards and guidelines of Universidad Peruana Cayetano Heredia's policies regarding the justification and control of Research Project expenditures, and we also applied other audit procedures we considered necessary.

Scope of the audit

The scope of our audit comprised the expenditures for the audited period, for which we applied audit procedures determined on the basis of our risk assessment, including selective testing of transactions and supporting documentation. As part of our audit procedures and to determine the adequate control environment, we reviewed the following documents:

- Agreements entered into between Universidad Peruana Cayetano Heredia and the National Institutes of Health - NIH.
- Sub-agreements entered into between Universidad Peruana Cayetano Heredia and universities of the United States of America, which receive NIH funding and subcontract UPCH's services to carry out the research.
- Project progress reports.
- Organizational charts.
- Accounting systems.
- Procurement, purchasing and contracting policies and procedures.

The audit procedures on the Statements of Expenditures of each NIH-funded Project included the budgeted amounts, reported expenditures and compliance with the procedures established in the contracts and subcontracts.

The review of the proper justification of the expenditures incurred by the audited Projects, ensuring they are supported by original documentation.

The review of purchasing procedures, procurement of goods, bidding processes and quotations.

The review of procedures for hiring payroll personnel and their statutory benefits.

The review of procedures for third-party services, contracts, technical reports and service acceptance certificates, in accordance with the nature of the service.

As part of our audit, we took into account the following standards:

- Standard Statement of Work for financial audits of NON-US organizations contracted.
- Generally Accepted Government Auditing Standards of the United States of America (GAGAS).
- The Compliance Supplement of the United States Office of Management and Budget (OMB) - 2 CFR Part 200.
- International Standards on Auditing (ISA).

V. FINANCIAL, ACCOUNTING AND ADMINISTRATIVE VERIFICATION

5.1 Main Accounting Policies

The main policies adopted by Universidad Peruana Cayetano Heredia in the preparation and presentation of the Statements of Expenditures of the Research Projects have been applied consistently and are presented below:

- a. The consolidated statement of expenditures of the Projects was prepared by the University on the cash disbursed/executed accounting basis; under this basis, expenditures are recognized on the date they are paid.

- b. The cost budget is based on the estimated amounts agreed between the cooperating entities and the University.
- c. The University records its transactions in soles, and for the conversion of the consolidated statement of expenditures of the Projects into US dollars, it uses the exchange rate as of the date the expenditure is recorded.

5.2 Audit procedures for expenditures of the Research Projects

The date of the expenditure documents corresponds to the audited period from January 1, 2025 to December 31, 2025. We verified that the expenditure documents of the Research Projects include only expenditures related to the funds contributed to the Research Projects, which are the subject of our audit.

Formal requirements of expenditures

We verified the original documents; invoices, receipts and other supporting documents for expenditures by budget line item, and that within each budget line item the information is organized by expenditure date, and that they are recorded in the Statements of Expenditures and in the accounting records of Universidad Peruana Cayetano Heredia.

We verified expenditures arising from the hiring of personnel dedicated in whole or in part to the Project, comprising salaries, social security, bonuses, vacation, severance compensation and other statutory labor benefits in accordance with law.

We verified that personnel hiring complied with national regulations and with the employment contracts, which specify obligations, type of hiring, professional category and salary.

We verified that employees' pay (compensation) is made monthly for each research Project, providing them with their respective pay slips as required by labor legislation, complying with the payment of bonuses, severance compensation, vacation, Essalud, among others. The allocation of an employee's salary varies depending on whether the employee is administrative staff or research staff, since administrative staff receive a fixed salary while researchers receive a fixed portion plus a variable portion corresponding to the Research Projects in which they participate.

We verified that payments of statutory benefits were made: bonuses, severance compensation and vacation.

Withholdings for pension funds, insurance and taxes are made in accordance with a detailed calculation and are paid to the collecting entity (AFPs, SUNAT) within the deadlines established by Peruvian labor law.

Universidad Peruana Cayetano Heredia maintains files where the following are kept in an orderly manner: personnel contracts, duly signed pay slips, with certificates of statutory benefit payments, certificates of tax withholdings, pension fund payments, tax payments, payroll payments and social security payments.

We verified that personnel files contain: hiring request, personnel contract, contract checklist, single personnel record form, police background check certificate, proof of residence, copy of national ID or foreign resident card, resume/CV, copy of degrees and/or titles, diplomas and academic transcripts.

We verified that duly signed personnel contracts are scanned and filed in a folder synchronized to Universidad Peruana Cayetano Heredia's cloud storage.

We verified that travel expenses are supported by settlements for lodging, local transportation and travel, made only for personnel with an employment relationship, with a list of supporting documents and their invoices, receipts and sworn statements.

We sufficiently and adequately verified the existence of the expenditure, confirming the reality and quality of the expenditure corresponding to a transaction or action, by examining evidence of the work performed, the goods received or the services rendered, on a regular basis, of acceptable and agreed-upon quality, and at reasonable prices or costs.

VI. INTERNAL CONTROL

We reviewed and evaluated Universidad Peruana Cayetano Heredia's internal control relating to the Research Projects, to obtain sufficient understanding of the design of the control policies and procedures, and whether those policies and procedures have been placed in operation.

The main audit procedures we applied to evaluate internal control are detailed below:

- a. We obtained a sufficient understanding of internal control to plan the audit and determine the nature, timing and extent of the tests to be performed.
- b. We assessed inherent risk and control risk, and determined detection risk. Inherent risk is the susceptibility of an assertion, such as an account balance, to a material misstatement, assuming there are no related internal control policies or procedures. Control risk is the risk that a material misstatement could occur in an assertion and not be prevented or detected on a timely basis by Universidad Peruana Cayetano Heredia's internal control, policies or procedures. Detection risk is the risk that a material misstatement existing in an assertion will not be detected. Detection risk is based on the effectiveness of an audit procedure and its application by the auditor.
- c. We summarized the risk assessments for each significant assertion in the working papers. The risk assessments have considered the following general categories under which each assertion must be classified:
 - Completeness
 - Existence
 - Accuracy
 - Valuation
 - Obligation
 - Presentation
- d. We evaluated the control environment, the adequacy of the accounting system and the control procedures. Emphasis was placed on the policies and procedures relevant to Universidad Peruana Cayetano Heredia's ability to record, process, summarize and report financial information consistent with the assertions contained in each account of the Consolidated Statement of Expenditures.

For this purpose, we evaluated, among others, the control systems for:

- i. Ensuring that charges to the program are appropriate and duly documented;
- ii. The procurement of goods and services;
- iii. The administration of personnel functions, such as time control, salaries and statutory benefits;
- iv. The administration and disposition of assets (such as equipment and supplies, among others) acquired for the Research Projects; and
- v. Ensuring compliance with the terms of the subcontracts, laws and applicable regulations that collectively have a significant impact on the Consolidated Statement of Expenditures.

VII. COMPLIANCE WITH THE TERMS OF THE CONTRACTS, SUBCONTRACTS, LAWS AND APPLICABLE REGULATIONS

To carry out the evaluation of compliance with the terms of the contracts, subcontracts, laws and applicable regulations, we designed an audit plan that considered, among other aspects, the performance of the following procedures:

- a. We identified, on a selective basis, the terms of the contracts, subcontracts, laws and relevant regulations, and determined which, if not observed, could have a direct and material effect on the Consolidated Statement of Expenditures. For this purpose:
 - I. We listed all the general and program-specific clauses contained in the contracts and subcontracts that, cumulatively, if not complied with, could have a direct and material effect on the Consolidated Statement of Expenditures.
 - II. We assessed inherent risk and control risk regarding the occurrence of a significant instance of noncompliance for each compliance requirement.
 - III. We determined the nature, timing and extent of the audit procedures to perform tests to determine whether misstatements, fraud and noncompliance exist, providing reasonable assurance of detecting instances of intentional or unintentional noncompliance with the terms of the subcontracts, applicable regulations and laws that could have a material effect on the Consolidated Statement of Expenditures.
- b. We determined, on a sample basis, whether payments were made in accordance with the terms of the contracts, subcontracts, applicable laws and regulations.
- c. We determined, on a sample basis, whether funds were spent for unauthorized purposes or were not in accordance with the applicable terms of the subcontracts.
- d. We determined, on a sample basis, whether the Projects' Statements of Expenditures reports, advance requests and reimbursements contain information that is supported by their accounting books and records.

- e. We determined a non-statistical selection of documents as a sample of expenditures, for which we have:
 - I. Verified whether expenditures incurred by the research Projects were authorized and/or approved by the principal investigator, with adequate supporting documentation.
 - II. Verified that the internal controls applied by Universidad Peruana Cayetano Heredia for the procurement of goods and services were complied with, in accordance with the approval levels and the minimum required number of quotations.
 - III. We validated that contracts exist for the procurement of a good or service, that the established deadlines were met, and that there is evidence of service acceptance or receipt of the goods.
 - IV. Verified the existence of original payment vouchers (invoices, receipts, tickets, others).
 - V. Verified that the documents supporting the expenditure are free of alterations.
- f. We determined a non-statistical selection of documents as a sample of cash advances to be accounted for, for which we have:
 - I. Verified whether cash advances to be accounted for by the research Projects were authorized and/or approved by the principal investigator, with adequate supporting documentation.
 - II. Validated that all funds were transferred and accounted for within the time stipulated by the requesting party.
 - III. Verified the transfer to Universidad Peruana Cayetano Heredia's account for the return of any excess cash advance.
- g. We determined a non-statistical selection of documents as a sample of contractual expenditures, for which we have:
 - I. Verified that the invoice includes the detail of expenditures incurred and that these were approved by the General Administration Office for submission to the funder.
 - II. Validated that the deadlines established in the subcontract for the submission of operating reports to the funder were met.
- h. We determined a non-statistical selection of documents by Project, for which we have:
 - I. Verified compliance with the submission of operating and financial reports to the funding entity.
 - II. Verified that the Overhead calculation, in accordance with NIH guidelines, was transferred to the cost centers and used for the purposes established in accordance with Universidad Peruana Cayetano Heredia's directives.

- i. We determined a non-statistical selection of documents as a sample of asset acquisitions, for which we have:
 - I. Verified compliance with the regulations applicable to the accounting classification of acquisitions, considering the US\$5,000 threshold and the other criteria established to determine their recognition as an asset or their classification as an expense or supply, as applicable.
 - II. Validated that assets acquired with Project funding were duly coded and inventoried by the University and recorded in the accounting records.
- j. We determined the Projects opened and closed in 2025, for which we have:
 - I. Reviewed the Project opening procedure and verified that the start dates match the contracts and subcontracts.
 - II. Reviewed the contracts, subcontracts and amendments to determine the closing date of each of the research Projects.
 - III. Verified compliance with the Project closing directive.
 - IV. Verified the accounting closing of the Project's cost center.

VIII. OPPORTUNITIES FOR IMPROVEMENT AND RECOMMENDATIONS**8.1 Non-significant internal control deficiency due to partial budget validation in the OFIPLAN system**

During the audit of the payroll process, it was identified that the OFIPLAN system, used for budget planning, execution and project alignment, is in a phase of partial implementation. As a result, the automated budget validation control prior to accounting entry is not enabled for all transactions. Specifically, critical transactions such as bonuses and adjustments charged to projects are excluded from this automated validation, requiring supplementary manual reviews and explanations by the area.

Criteria: Internal control standards and good IT governance practices require that financial and payroll transactions have comprehensive, automated and preventive controls that ensure budget availability prior to their execution and recording, minimizing manual intervention.

Risk: This situation weakens the internal control environment and exposes the entity to the following risks:

- Execution of unauthorized expenditures or expenditures exceeding the budget ceilings of the projects.
- Loss of traceability and operational delays from reliance on manual validations and late explanations.

As a result of the evaluation performed, it was determined that the identified situation constitutes a non-significant internal control deficiency, because budget validation is partially implemented and there are complementary manual controls that mitigate the associated risks while the implementation of OFIPLAN is completed.

The identified deficiency was not considered significant for purposes of the auditor's conclusion, considering its nature, scope, impact and the existing compensating controls. Nevertheless, it is considered appropriate to communicate it to Management in order to strengthen the control environment and reduce reliance on manual procedures.

Recommendation

That the University complete the implementation of automated budget validations in OFIPLAN for all transactions with an impact on projects, including bonuses and adjustments, additionally establishing formal compensating controls until implementation is completed.

University's comments

Although the process is currently controlled and the research projects have been reconciled, the University's new management is evaluating the operation and benefits provided by the OFIPLAN system, particularly with regard to the budget control mechanisms applicable to payroll expenditures associated with research projects.

As a result of this evaluation, the improvements and implementations necessary to strengthen process automation, ensure adequate budget control and improve information traceability will be determined, progressively reducing manual validation activities.

In this context, the Information Technology Department is evaluating alternatives aimed at increasing the level of process automation and integration. The proposals arising from this evaluation will be submitted to the relevant authorities, who, based on technical, operational and institutional capacity criteria, will determine the appropriate actions to optimize the process and strengthen the existing internal controls, either by improving OFIPLAN's functionalities or, if necessary, by implementing an alternative technology solution

IX. FOLLOW-UP ON RECOMMENDATIONS FROM PRIOR PERIODS

The recommendations resulting from prior years and their current status are presented below:

- 9.1. Dates recorded in project contracts and/or subcontracts differ from the dates reported in the Consolidated Statements of Expenditures** During the audit of the 2023 consolidated statement of expenditures, it was identified that some project completion dates did not match those established in their amendments. This situation was due to the lack of a directive to timely update the ERP system in response to contractual modifications.

The identified cases are presented below:

N° Proyecto	Fecha de término del Proyecto	
	Según sistema Oracle	Según adendas
Proyecto 94	30/06/2024	30/06/2027
Proyecto 79	30/06/2024	29/09/2024
Proyecto 60	3/06/2024	31/05/2024
Proyecto 23	30/06/2023	14/06/2023
Proyecto 61	14/06/2026	15/04/2026
Proyecto 84	30/04/2023	31/01/2023
Proyecto 46	1/03/2023	31/12/2027
Proyecto 35	4/11/2018	28/02/2023
Proyecto 18	31/05/2026	31/05/2028

Actions taken by the University

Universidad Peruana Cayetano Heredia's General Administration has updated the dates and prepared a PPT presentation on the process for opening and modifying data in the ORACLE ERP system for research projects.

Current status

As of the date of this report, the General Projects Administration has corrected this situation in the ORACLE-PM system.

- 9.2. Absence of administrators in some Projects** During the execution of the 2023 audit, there was some delay in the delivery of accounting information by the University, mainly because some Research Projects did not have a dedicated Administrator assigned exclusively; or, failing that, the Principal Investigator performed the Administrator's functions. The identified Projects are presented below:

N° Proyecto	Importe ejecutado	
	US\$	S/
Proyecto 86 Nih-Receptores Huérfanos	18,875	70,077
Proyecto 56 Multidisciplinary Training Program on Neuropsychiatry and behavioral disorders in First Nations (NEUFIN)	80,127	299,805
Proyecto 2 Program for advanced research capacities for AIDS in Perú (Paracas) harnessing implementation science	229,604	857,444
Proyecto 57 Isolation and identification of CXCR4 and CXCR7 agonists from traditional phytopharmaceuticals as potential novel drugs for mental disorders	41,897	157,692

Actions taken by the University

Currently, all projects have an assigned administrator, except for four cases still managed by researchers. A progressive process has been initiated to transfer administration to specialized personnel, including the allocation of proportional workload. In addition, controls have been implemented so that new projects include budget for an administrator.

Current status

As of the date of this report, this situation has been corrected; the General Projects Administration has assigned a manager or administrator to each of the projects. Each project manager is responsible for a principal investigator.

9.3. Difference between the project management module and the accounting module

As of October 1, 2023, the University acquired a new Oracle Cloud ERP, made up of different modules, including GL (General Ledger) and PM (Project Management); both modules process information under the following parameters:

PM (módulo de proyectos)	GL (módulo contable)
Número de proyecto	Número de proyecto
Tarea (partida presupuestal)	-----
Tipo de gasto (cuenta contable)	Cuenta contable
Moneda en S/ y US\$	-----
-----	Moneda en S/

Differences were identified between the accounting modules by budget line item and currency type, for which reason Management must reconcile balances in soles and dollars by account and line item. However, this process does not yet have a formal methodology for preparing expenditure reports to be submitted to cooperating entities and auditors.

Actions taken by the University

We consider the observation to be procedural rather than material in nature; however, work is underway on a formal reconciliation and expenditure reporting methodology that includes periodic reconciliation of the accounting and budget modules.

Current status

As of the date of this report, the reconciliations have been implemented; the General Projects Administration uses the project modules together with the accounting module to issue expenditure reports, in which it determines the following parameters: period type, budget period, currency and project award.

Panez, Chacaliza & Asociados S.C.R. Ltda.
Av. De La Floresta 497, oficina 203
Chacarilla del Estanque
San Borja, Lima-Perú
T: +51 (1) 6128383
www.rsm.global/peru/es

Panez, Chacaliza & Asociados S.C.R. Ltda. está relacionado con RSM Perú S.A.C., que es miembro de la red RSM y comercializa como RSM. RSM es el nombre comercial utilizado por los miembros de la red RSM. Cada miembro de la red RSM es una firma de consultoría y contabilidad independientes que operan por derecho propio. La red RSM no es en sí misma una entidad legal separada en ninguna jurisdicción.

La red RSM es administrada por RSM International Limited, una compañía registrada en Inglaterra y Gales (número de compañía 4040598) cuya oficina registrada se encuentra en 50 Cannon street, London, EC4N 6JJ.

La marca y nombre registrado RSM y otros derechos de propiedad intelectual usados por miembros de la red son propiedad de la Asociación Internacional RSM, una asociación gobernada por el artículo 60 y siguientes del Código Civil de Suiza cuyos asientos están en Zug.

© RSM International Association